Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer

Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targ...

Full description

Saved in:
Bibliographic Details
Published inTechnology in cancer research & treatment Vol. 22; p. 15330338231178403
Main Authors Dey, Amit, Mitra, Abhijit, Pathak, Surajit, Prasad, Suhanya, Zhang, Alexander Sun, Zhang, Hong, Sun, Xiao-Feng, Banerjee, Antara
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 2023
Sage Publications Ltd
SAGE Publishing
Subjects
Advances in the Diagnosis and Treatment of Gastrointestinal Cancers
Biomarkers
Biomarkers, Tumor - genetics
Cancer therapies
Chemotherapy
Colon cancer
Colonic Neoplasms - diagnosis
Colonic Neoplasms - genetics
Colonic Neoplasms - therapy
Colorectal cancer
Epigenetics
Genetic diversity
Health care
Humans
Immunotherapy
Patients
personalized treatment
Precision medicine
Precision Medicine - methods
targeted therapy
Transcriptomics
targeted therapy
precision medicine
colon cancer
personalized treatment
immunotherapy
Online AccessGet full text
ISSN1533-0346
1533-0338
1533-0338
DOI10.1177/15330338231178403

Cover

Abstract Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.
AbstractList Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.
Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patient's personal history. It is based on the response of the targeted therapies to specific genetic variations. The patient's genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.
Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with the process are considered in personalized medicine, along with the patients personal history. It is based on the response of the targeted therapies to specific genetic variations. The patients genetic transcriptomic and epigenetic features are evaluated, and the best therapeutic approach and diagnostic testing are identified through personalized medicine. This review aims to summarize all the necessary, updated information on colon cancer related to personalized medicine. Personalized medicine is gaining prominence as generalized treatments are finding it challenging to contain colon cancer cases which currently rank fourth among global cancer incidence while being the fifth largest in total death cases worldwide. In personalized therapy, patients are grouped into specific categories, and the best therapeutic approach is chosen based on evaluating their molecular features. Various personalized strategies are currently being explored in the treatment of colon cancer involving immunotherapy, phytochemicals, and other biomarker-specific targeted therapies. However, significant challenges must be overcome to integrate personalized medicine into healthcare systems completely. We look at the various signaling pathways and genetic and epigenetic alterations associated with colon cancer to understand and identify biomarkers useful in targeted therapy. The current personalized therapies available in colon cancer treatment and the strategies being explored to improve the existing methods are discussed. This review highlights the advantages and limitations of personalized medicine in colon cancer therapy. The current scenario of personalized medicine in developed countries and the challenges faced in middle- and low-income countries are also summarized. Finally, we discuss the future perspectives of personalized medicine in colon cancer and how it could be integrated into the healthcare systems.
Author Banerjee, Antara
Pathak, Surajit
Zhang, Hong
Mitra, Abhijit
Sun, Xiao-Feng
Prasad, Suhanya
Dey, Amit
Zhang, Alexander Sun
AuthorAffiliation 1 Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Chettinad Hospital and Research Institute, Chennai, India
2 Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, Białystok, Poland
5 Department of Oncology and Department of Biomedical and Clinical Sciences, 4566 Linköping University , Linköping, Sweden
4 School of Medicine, Department of Medical Sciences, 6233 Orebro University , Örebro, Sweden
3 Department of Oncology-Pathology, 27106 Karolinska Institute , Solna, Sweden
AuthorAffiliation_xml – name: 5 Department of Oncology and Department of Biomedical and Clinical Sciences, 4566 Linköping University , Linköping, Sweden
– name: 1 Faculty of Allied Health Sciences, Chettinad Academy of Research and Education, Chettinad Hospital and Research Institute, Chennai, India
– name: 4 School of Medicine, Department of Medical Sciences, 6233 Orebro University , Örebro, Sweden
– name: 3 Department of Oncology-Pathology, 27106 Karolinska Institute , Solna, Sweden
– name: 2 Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, Białystok, Poland
Author_xml – sequence: 1
  givenname: Amit
  surname: Dey
  fullname: Dey, Amit
– sequence: 2
  givenname: Abhijit
  surname: Mitra
  fullname: Mitra, Abhijit
– sequence: 3
  givenname: Surajit
  surname: Pathak
  fullname: Pathak, Surajit
– sequence: 4
  givenname: Suhanya
  surname: Prasad
  fullname: Prasad, Suhanya
– sequence: 5
  givenname: Alexander Sun
  surname: Zhang
  fullname: Zhang, Alexander Sun
– sequence: 6
  givenname: Hong
  surname: Zhang
  fullname: Zhang, Hong
– sequence: 7
  givenname: Xiao-Feng
  surname: Sun
  fullname: Sun, Xiao-Feng
  email: xiao-feng.sun@liu.se
– sequence: 8
  givenname: Antara
  orcidid: 0000-0002-5519-6878
  surname: Banerjee
  fullname: Banerjee, Antara
  email: antarabanerjee@care.edu.in
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37248615$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-195329$$DView record from Swedish Publication Index
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-106108$$DView record from Swedish Publication Index
http://kipublications.ki.se/Default.aspx?queryparsed=id:152783934$$DView record from Swedish Publication Index
BookMark eNqNkk1vEzEQhleoiH7AD-CCVuLCgRR_e_eEokChUhAIFa6W1zubOmzsYO8G0V-P3aSFFFFx8nj8zDuv7TkuDpx3UBRPMTrFWMpXmFOKKK0ITduKIfqgOMq5SU4e3MZMHBbHMS4RIkJQ_Kg4pJKwSmB-VFx9BgNuKKftRjsDqxTHl-XcruygB-td2mjXlmfjMAYoP0GIazCD3UAsfVcOl1COEXKYj7zTvb2CtvwArTXWQWldeRFAD1k3UzPfe1fOcqvwuHjY6T7Ck916Unw5e3sxez-Zf3x3PpvOJ0YwOUxw3VUgalkT3QhEOQXeIsFaCS2WyPCa1khyYB3poGtYQzRvDQiRKNJJ09GT4nyr23q9VOtgVzr8VF5bdZ3wYaF0GKzpQVEtGEO6YryTLD1to2tKGDZ1gzjUnCetyVYr_oD12Oyp7VLfUgRKCFKJ-l7-jf06ve7uw6gwEhhV_8f3NvE1pyTrv97yCV5Bm78y6H6vbP_E2Uu18JvUjzBUVTgpvNgpBP99hDiolY0G-l478GNUpCKoFrKSudnzO-jSjyH9eaZqlG6Mqkw9-9PSrZebmUuA3AIm-BgDdMrshi05tH2ypvJ0q7-mO1XiO5U34vfVnO5eVC_gt-F_F_wClbUIfQ
CitedBy_id crossref_primary_10_1016_j_compbiomed_2025_109672
crossref_primary_10_3390_cancers16213690
crossref_primary_10_1016_j_bmcl_2024_130069
crossref_primary_10_1186_s12951_024_02913_7
crossref_primary_10_1021_acsptsci_4c00008
crossref_primary_10_1038_s41598_024_72818_w
crossref_primary_10_3390_medicina59122194
crossref_primary_10_3389_fonc_2024_1384342
crossref_primary_10_2217_bmm_2023_0212
crossref_primary_10_1002_jbt_23771
crossref_primary_10_1016_j_jpi_2024_100408
crossref_primary_10_1080_01635581_2024_2361964
crossref_primary_10_7759_cureus_73694
crossref_primary_10_3390_app14010355
crossref_primary_10_1007_s10637_024_01488_2
crossref_primary_10_1002_cbf_3906
crossref_primary_10_5306_wjco_v15_i9_1136
crossref_primary_10_7759_cureus_48796
crossref_primary_10_1002_fsn3_4669
crossref_primary_10_2174_012212697X308365240529100442
crossref_primary_10_1016_j_prp_2024_155546
crossref_primary_10_1097_JS9_0000000000001175
crossref_primary_10_1016_j_talanta_2023_124996
crossref_primary_10_3390_jcm13216578
crossref_primary_10_3390_cancers16132379
crossref_primary_10_1016_j_intimp_2024_113325
crossref_primary_10_1089_lap_2024_0347
crossref_primary_10_1007_s12291_024_01261_5
crossref_primary_10_7759_cureus_71040
crossref_primary_10_7759_cureus_77524
crossref_primary_10_1007_s12026_024_09478_5
crossref_primary_10_1016_j_ijbiomac_2024_135394
crossref_primary_10_1007_s11044_025_10052_6
crossref_primary_10_1016_j_carbpol_2024_122935
crossref_primary_10_3390_ijms26062448
crossref_primary_10_4018_IJHISI_351244
crossref_primary_10_1016_j_heliyon_2024_e34316
crossref_primary_10_1016_j_ejmech_2025_117535
Cites_doi 10.1007/s00464-021-08655-z
10.1016/j.ctrv.2021.102218
10.3390/ph14111077
10.1016/0092-8674(90)90186-I
10.1016/j.ejso.2022.12.005
10.1016/j.clinre.2012.10.005
10.1053/j.gastro.2021.09.074
10.1517/14712598.2013.810717
10.1093/annonc/mdw235
10.3892/ol.2016.4576
10.1042/EBC20190037
10.1002/cncy.22525
10.1038/s41388-020-1351-z
10.3390/jpm2010001
10.1126/science.2649981
10.1200/JCO.20.02088
10.14740/wjon1345
10.18632/oncotarget.15030
10.1080/09553002.2018.1400191
10.1093/annonc/mdu499
10.1016/j.bbrc.2014.07.007
10.3390/cancers14112664
10.1056/NEJMra0804588
10.18632/oncotarget.5815
10.3390/biomedicines10051035
10.3390/cancers14092241
10.1136/esmoopen-2019-000638
10.31083/j.fbl2706189
10.1016/j.jviscsurg.2021.04.002
10.1016/j.jmb.2021.167256
10.1007/s40265-021-01501-5
10.3390/cancers14153647
10.1093/annonc/mdu217
10.1371/journal.pone.0264138
10.3390/ijms18010197
10.1001/jamaoncol.2021.8196
10.1016/j.bbcan.2022.188827
10.3390/curroncol29040216
10.1053/j.gastro.2015.06.047
10.31557/APJCP.2022.23.5.1517
10.1016/j.oooo.2020.06.014
10.1155/2020/5432651
10.2174/1871530320666200515115723
10.3390/jpm11020135
10.1007/s10555-017-9725-6
10.3390/jpm10040168
10.1093/annonc/mdx738
10.1038/s41598-022-21582-w
10.3390/ijms23063252
10.18632/oncotarget.22471
10.1016/j.celrep.2019.10.093
10.4251/wjgo.v14.i4.833
10.1038/s41573-021-00345-8
10.3390/cancers10020038
10.1016/j.tranon.2018.12.003
10.1007/s00394-022-02984-y
10.1038/s41598-022-16274-4
10.3390/cells12010138
10.1158/2159-8290.CD-21-0680
10.1200/JCO.2017.35.15_suppl.TPS3630
10.3390/cancers13246363
10.3390/pharmaceutics14122737
10.1093/pcmedi/pbac005
10.3390/ijms22010130
10.18632/oncotarget.27304
10.1038/s41598-021-99269-x
10.3390/pharmaceutics14040692
10.1097/01.pai.0000213141.47277.bf
10.1016/j.tranon.2018.11.009
10.1053/j.gastro.2010.01.054
10.1200/JCO.2015.63.2471
10.1021/acs.jproteome.2c00551
10.3390/polym15030542
10.1186/gm545
10.3322/caac.21660
10.1016/j.ejca.2019.11.016
10.1055/s-0041-1742115
10.1200/JCO.2015.63.2497
10.2147/OTT.S340392
10.1053/j.gastro.2019.08.059
10.1358/dot.2005.41.2.882662
10.1039/c3fo60417a
10.1111/jgh.15937
10.1080/21645515.2016.1175694
10.1056/NEJMoa022289
10.1186/s12967-021-02910-6
10.1200/JCO.2017.76.9901
10.1007/978-981-16-4752-9_24
10.1016/S1470-2045(22)00274-1
10.1200/JCO.20.01600
10.1001/jamaoncol.2018.5070
10.3389/fonc.2014.00035
10.1007/s10555-020-09913-7
10.1038/s41416-020-01147-2
10.14740/gr1239
10.1186/s13023-021-01929-8
10.3747/co.v18i1.708
10.3390/medicina59040685
10.3390/antib11010006
10.3748/wjg.14.378
10.1158/2159-8290.CD-12-0471
10.1158/1078-0432.CCR-13-2944
10.1093/annonc/mdy461
10.1002/cam4.4216
10.1056/NEJMoa1609279
10.1158/1078-0432.CCR-19-2004
10.1186/s12876-021-01864-9
10.17265/2159-5313/2016.09.003
10.1158/0008-5472.CAN-11-2612
10.1055/a-1637-9051
10.1126/science.7761852
10.3390/cancers11020172
10.1200/JCO.2016.71.4394
10.2147/CMAR.S216220
10.1093/annonc/mdx030
10.1016/j.immuni.2016.01.024
10.1016/S1470-2045(14)71168-4
10.1038/s41374-022-00804-9
10.1186/s13046-022-02591-z
10.1016/j.critrevonc.2021.103537
10.18632/oncotarget.17466
10.1016/j.esmoop.2022.100400
10.3390/scipharm90020036
10.1056/NEJMoa1917239
10.2174/1568009619666191114110359
10.1111/cas.12907
10.1053/j.gastro.2022.05.032
10.1016/j.stemcr.2022.12.013
10.1007/s12325-018-0791-0
10.1200/JCO.2010.30.1366
10.1016/j.ejmg.2019.103753
10.1056/NEJMoa1908075
10.1200/EDBK_349557
10.3390/cancers12092679
10.21037/jgo.2019.05.01
10.1038/bjc.2015.399
10.1056/NEJMoa2017699
10.1158/2159-8290.CD-16-0795
10.1016/j.semcancer.2022.03.018
10.1136/gut.2010.217182
10.3390/ijms23169302
10.1007/s00384-021-04064-9
10.1200/JCO.2013.48.9591
10.1002/ijc.33599
10.1038/s12276-022-00731-1
10.1126/science.1096502
10.1002/path.5868
10.3390/cancers14071732
10.3390/cancers12041022
10.1016/j.tig.2022.02.010
10.15252/msb.20145645
10.3390/ijms23136911
10.1002/jcb.27275
10.1001/jamaoncol.2015.5511
10.1053/j.gastro.2008.07.076
10.1016/j.bbrc.2022.09.046
10.3390/ijms23169455
10.1056/EVIDra2100035
10.3389/fonc.2019.00001
10.1038/s41418-022-00975-4
10.3390/ijms20122919
10.1186/s12885-022-09947-w
10.1158/1078-0432.CCR-14-2779
10.1146/annurev-pathmechdis-012418-012818
10.1080/13543784.2022.2040016
10.1073/pnas.96.15.8681
ContentType Journal Article
Copyright The Author(s) 2023
The Author(s) 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023 2023 SAGE Publications
Copyright_xml – notice: The Author(s) 2023
– notice: The Author(s) 2023. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023 2023 SAGE Publications
DBID AFRWT
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
7X8
5PM
ABXSW
ADTPV
AOWAS
D8T
DG8
ZZAVC
AABEP
D91
DOA
DOI 10.1177/15330338231178403
DatabaseName Sage Journals Online Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Oncogenes and Growth Factors Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection (ProQuest)
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
SWEPUB Linköpings universitet full text
SwePub
SwePub Articles
SWEPUB Freely available online
SWEPUB Linköpings universitet
SwePub Articles full text
SWEPUB Örebro universitet full text
SWEPUB Örebro universitet
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic
CrossRef
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: AFRWT
  name: Sage Journals Online Open Access
  url: http://journals.sagepub.com/
  sourceTypes: Publisher
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1533-0338
ExternalDocumentID oai_doaj_org_article_3a6440a845f74303ba93241c9b05e955
oai_swepub_ki_se_662869
oai_DiVA_org_oru_106108
oai_DiVA_org_liu_195329
PMC10240881
37248615
10_1177_15330338231178403
10.1177_15330338231178403
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: Science and Engineering Research Board
  grantid: EMR/2017/001877
  funderid: https://doi.org/10.13039/501100001843
– fundername: ;
  grantid: EMR/2017/001877
GroupedDBID ---
-TM
0R~
123
53G
54M
7X7
8FI
8FJ
AABMB
AADCB
AADUE
AAJPV
AAJQC
AARDL
AARIX
AASGM
ABAWP
ABEIX
ABFWQ
ABKRH
ABQXT
ABRHV
ABUWG
ABVFX
ACARO
ACDSZ
ACDXX
ACGFS
ACOFE
ACROE
ADBBV
ADOGD
ADPDF
ADZZY
AENEX
AEQLS
AERKM
AEUHG
AEWDL
AEXNY
AFCOW
AFEET
AFKRA
AFKRG
AFRWT
AFUIA
AGNHF
AJUZI
ALIPV
ALJHS
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AUTPY
AYAKG
B8M
BDDNI
BENPR
BKSCU
BPHCQ
BSEHC
BVXVI
CCPQU
CDWPY
CFDXU
DC-
DC.
DOPDO
EBS
EJD
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION
H13
HMCUK
HYE
J8X
K.F
O9-
OK1
OVD
OVEED
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
ROL
RPM
SAUOL
SCDPB
SCNPE
SFC
SJN
TEORI
UDS
UKHRP
Y4B
ZONMY
ZPPRI
ZRKOI
ZSSAH
AAYXX
ACHEB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7TO
7XB
8FK
AZQEC
DWQXO
H94
K9.
PKEHL
PQEST
PQUKI
7X8
5PM
ABXSW
ADTPV
AOWAS
D8T
DG8
ZZAVC
AABEP
D91
PUEGO
ID FETCH-LOGICAL-c647t-19f8e69792ab60353e5d064d7ed170c5939075e4f2fefb4b2a5dce665d02f7cf3
IEDL.DBID DOA
ISSN 1533-0346
1533-0338
IngestDate Wed Aug 27 01:08:41 EDT 2025
Mon Sep 01 03:32:37 EDT 2025
Thu Aug 21 06:49:38 EDT 2025
Thu Aug 21 06:48:37 EDT 2025
Thu Aug 21 18:38:07 EDT 2025
Fri Jul 11 15:16:56 EDT 2025
Mon Jun 30 10:55:18 EDT 2025
Mon Jul 21 06:17:35 EDT 2025
Tue Jul 01 05:24:53 EDT 2025
Thu Apr 24 23:10:46 EDT 2025
Tue Jun 17 22:27:32 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords targeted therapy
precision medicine
colon cancer
personalized treatment
immunotherapy
Language English
License This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c647t-19f8e69792ab60353e5d064d7ed170c5939075e4f2fefb4b2a5dce665d02f7cf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
Authors contributed equally.
ORCID 0000-0002-5519-6878
OpenAccessLink https://doaj.org/article/3a6440a845f74303ba93241c9b05e955
PMID 37248615
PQID 2890628089
PQPubID 4450582
ParticipantIDs doaj_primary_oai_doaj_org_article_3a6440a845f74303ba93241c9b05e955
swepub_primary_oai_swepub_ki_se_662869
swepub_primary_oai_DiVA_org_oru_106108
swepub_primary_oai_DiVA_org_liu_195329
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10240881
proquest_miscellaneous_2820967879
proquest_journals_2890628089
pubmed_primary_37248615
crossref_citationtrail_10_1177_15330338231178403
crossref_primary_10_1177_15330338231178403
sage_journals_10_1177_15330338231178403
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – year: 2023
  text: 2023
PublicationDecade 2020
PublicationPlace Los Angeles, CA
PublicationPlace_xml – name: Los Angeles, CA
– name: United States
– name: Thousand Oaks
– name: Sage CA: Los Angeles, CA
PublicationTitle Technology in cancer research & treatment
PublicationTitleAlternate Technol Cancer Res Treat
PublicationYear 2023
Publisher SAGE Publications
Sage Publications Ltd
SAGE Publishing
Publisher_xml – name: SAGE Publications
– name: Sage Publications Ltd
– name: SAGE Publishing
References Kopetz, Desai, Chan 2015; 33
Wang, Sun, Lei, Zhang 2022; 86
Carethers, Jung 2015; 149
Kloypan, Koomdee, Satapornpong, Tempark, Biswas, Sukasem 2021; 14
Nistal, Fernández-Fernández, Vivas, Olcoz 2015; 5
Nguyen, Thi, Nguyen, Nguyen, Trung 2022; 23
Huijberts, Boelens, Bernards, Opdam 2021; 124
Mármol, Sánchez-de-Diego, Pradilla Dieste, Cerrada, Rodriguez Yoldi 2017; 18
Hou, Zheng, Wei, Zhao 2022; 13
Ebert, Cheung, Yang 2016; 44
Patil, Jahagirdar, Khot, Sengupta 2022; 434
Wu, Reid, Leedham, Lui 2022; 37
Ogino, Chan, Fuchs, Giovannucci 2011; 60
Abraham, Khandelwal, Hintzsche, Stopper 2016; 31
Amerizadeh, Rahmani, Maftooh 2022; 77
Prior, Lewis, Mattos 2012; 72
Wulaningsih, Wardhana, Watkins, Yoshuantari, Repana, Van Hemelrijck 2016; 2
Kazama, Shiozawa, Numata 2022; 37
Ma, Huang, Chang 2019; 12
Kang, Ko, Kil 2023; 1878
Koh, Tan 2019; 10
Pathak, Banerjee, Meng, Nandy, Gopinath, Sun 2018; 94
Lin, Wu, Chu, Ouyang 2022; 630
Daisy Precilla, Biswas, Kuduvalli, Anitha 2022; 95
Corcoran, Atreya, Falchook 2015; 33
Helsingen, Kalager 2022; 1
Xu, Wu, Zhang 2019; 29
Samuels, Wang, Bardelli 2004; 304
Vannijvel Albert 2022; 35
Zeller, Tap, Voigt 2014; 10
Hutchins, Southward, Handley 2011; 29
Milbury, Creeden, Yip 2022; 17
Mutignani, Penagini, Gargari 2021; 13
Cathomas 2014; 4
Papaccio, García-Mico, Gimeno-Valiente 2023; 42
Yaeger, Kotani, Mondaca 2019; 25
Kopetz, Grothey, Yaeger 2019; 381
Lee, Song, Jang 2021; 149
Mishra 2022; 162
Overman, Lonardi, Wong 2018; 36
Ciardiello, Arnold, Casali 2014; 25
Lee, Dho, Lee 2022; 54
Huang, Yang 2022; 12
You, Zhou, Xin 2022; 5
Yang, Yang, Ji 2022; 146
Bhattacharyya, Chehal, Migliorati 2020; 130
Moutafi, Robbins, Yaghoobi 2022; 102
Jones, Renfro, Al-Shamsi 2017; 35
Efferth, Saeed, Mirghani 2017; 8
Razali, Lam, Rajab, Jamal, Kamaluddin, Chan 2022; 12
Skvortsova, Stirzaker, Taberlay 2019; 63
Osterburg, Dötsch 2022; 29
Braumüller, Mauerer, Andris, Berlin, Wieder, Kesselring 2023; 12
Ottaiano, Caraglia 2021; 11
Glimelius, Stintzing, Marshall, Yoshino, de Gramont 2021; 98
Ji, Wang, Fakih 2022; 15
Wang, Chao, Liu 2019; 18
Mao, Seow, Chen 2022; 23
Kudchadkar, Ahmed, Mukherjee, Sagar 2022; 14
Oneda, Zaniboni 2022; 169
Xie, Itzkowitz 2008; 14
Lebrun, Turpin, Zerbib 2021; 158
Yanus, Akhapkina, Iyevleva 2020; 63
Harding, Burtness 2005; 41
Canaud, Hammill, Adams, Vikkula, Keppler-Noreuil 2021; 16
Taha, Aboulwafa, Zedan, Helmy 2022; 12
Torrente-López, Hermosilla, Salmerón-García, Cabeza, Navas 2022; 14
Lau, Kalaitzaki, Church 2020; 5
Yi, Li, Long 2020; 39
Markowitz, Wang, Myeroff 1995; 268
Barkhatov, Aghayan, Scuderi 2022; 36
Ahmed 2020; 13
Turati, Concina, Rossi 2022; 62
Nagao, Koshino, Sugimura-Nagata 2022; 23
Nguyen, Duong 2018; 16
Zwager, Bastiaansen, Van Der Spek 2022; 54
Novellasdemunt, Kucharska, Baulies 2023; 18
Verma 2012; 2
Fearon, Vogelstein 1990; 61
Tran, Robbins, Lu 2016; 375
Banias, Jung, Chiciudean, Gurzu 2022; 23
Zhang, Sun, Shen, Zhang 2019; 11
Gul 2022; 3
Fornasier, Francescon, Baldo 2018; 35
Girigoswami, Girigoswami 2021; 21
van Geel, Tabernero, Elez 2017; 7
Das, Adhikari, Deka 2023; 59
Safarzadeh, Sandoghchian Shotorbani, Baradaran 2014; 4
Cohen, Taieb, Fiskum 2021; 39
Khan, Wilkerson, Vassos 2022; 49
Toyota, Ahuja, Ohe-Toyota, Herman, Baylin, Issa 1999; 96
Pathak, Meng, Nandy 2015; 6
Scarabel, Polesel, De Mattia 2022; 14
Sinicrope, Mahoney, Smyrk 2013; 31
De Luca, Marino, Maio, Ramucirumab 2020; 12
Sung, Ferlay, Siegel 2021; 71
Zhang, Zhang, Fan, Hildesjö, Shen, Sun 2022; 14
Alcindor, Beauger 2011; 18
Loupakis, Moretto, Aprile 2016; 114
Sherman, Lange, Dahdaleh 2019; 5
Tarighati, Keivan, Mahani 2022; 23
Adeniji, Dulal, Martin 2021; 12
Malki, ElRuz, Gupta, Allouch, Vranic, Al Moustafa 2020; 22
Lee, Li, Li 2022; 12
Hartl, de Luca, Kostikova 2021; 19
Zhang, Zhang, Shen, Sun 2019; 20
Jasperson, Tuohy, Neklason, Burt 2010; 138
Yamamoto, Oshima, Wang 2022; 257
Rajan, Kim, Heery, Guha, Gulley 2016; 12
Auclin, Zaanan, Vernerey 2017; 28
Pokorska-Bocci, Kroese, Sagoo, Hall, Burton 2014; 6
Cho, Kim, Che 2022; 23
Mazué, Delmas, Murillo, Saleiro, Limagne, Latruffe 2014; 5
Rodriguez 2013; 4
Sekita-Hatakeyama, Fujii, Nishikawa 2022; 130
Rahman, Ali, Rahamathulla, Salam, Mittal, Harwansh 2023; 15
Korman, Garrett-Thomson, Lonberg 2022; 21
Wen, Zhao, Holmqvist 2020; 10
Yu, Kopetz 2021; 19
Huyghe, Benidovskaya, Stevens, Van den Eynde 2022; 14
Shahi Thakuri, Luker, Tavana 2019; 12
Gao, Yang 2020; 20
Parmar, Easwaran 2022; 10
Matsunaga, Kaneta, Miwa 2016; 12
Yaeger, Cercek, Reilly 2015; 21
Buckley, Kakar 2007; 15
Van Cutsem, Cervantes, Adam 2016; 27
Hong, Fakih, Strickler 2020; 383
Klingbiel, Saridaki, Roth, Bosman, Delorenzi, Tejpar 2015; 26
Jin, Han, Lee 2022; 163
Ogino, Nowak, Hamada, Milner, Nishihara 2019; 14
Chen, Wei, Yu, Zhang 2014; 20
Clarke, Hurwitz 2013; 13
Pathak, Sushmitha, Banerjee 2018; 9
Yamai, Ikezawa, Kawamoto 2022; 29
André, Shiu, Kim 2020; 383
Lisi, Lacal, Martire, Navarra, Graziani 2022; 175
Gong, Cho, Sy, Salgia, Fakih 2017; 8
Zuo, Wu, Xiao 2018; 119
Baker, Fearon, Nigro 1989; 244
Vargas, Puga, Lenz, Trindade, Filippi-Chiela 2020; 2020
Hossain, Karuniawati, Jairoun 2022; 14
Yoshino, Arnold, Taniguchi 2018; 29
Rosati, Aprile, Colombo 2022; 10
Strickler, Yoshino, Graham, Siena, Bekaii-Saab 2022; 8
Qari, Alzahrani, Alzahrani, Saleh, Almasabi, Bawazir 2022; 14
Taieb, Gallois 2020; 12
Huang, Liu, Kang 2022; 83
Ribic, Sargent, Moore 2003; 349
Takigawa, Kitadai, Shinagawa 2016; 107
Goulet, Chatterjee, Lee, Waight, Zhu, Mak 2022; 11
Nguyen, Goel, Chung 2020; 158
Suzuki, Yamamoto, Maruyama, Niinuma, Kai 2014; 455
Patel, Sun 2014; 8
Lakatos, Köhne, Bodoky 2020; 39
André, Cohen, Salem 2022; 42
Al-Salama 2021; 81
Yoshino, Portnoy, Obermannová 2019; 30
Traversi, Pulliero, Izzotti 2021; 11
Dijkstra, Neikes, Rezaeifard 2023; 22
Vilar, Tabernero 2013; 3
Rossi, Jahanzaib Anwar, Usman, Keshavarzian, Bishehsari 2018; 10
Markowitz, Bertagnolli 2009; 361
Grady, Carethers 2008; 135
Sara, Kaur, Khodadadi 2018; 10
Tabernero, Grothey, Van Cutsem 2021; 39
Croce, Coperchini, Magri, Chiovato, Rotondi 2019; 10
Gelsomino, Casadei-Gardini, Rossini 2020; 12
Gürel, Çapkın, Parlar 2022; 90
El-Deiry, Winer, Slifker 2019; 9
De’ Angelis, Bottarelli, Azzoni 2018; 89
Hankey, Frankel, Groden 2018; 37
van den Berg, Schaap, Voogt 2022; 22
Garcia FA de, de Andrade, de Campos Reis Galvão 2022; 12
Bertelsen, Neuenschwander, Jansen 2015; 16
Rehman, Awais, Baloch 2016; 2
Delibegovic 2017; 71
Picasso, Parodi, Fisher, Blanchi, Conio 2013; 37
Pericleous, Bhogal, Mavroeidis 2022; 27
Fang, Liang, Wang 2021; 21
Di Liddo, Verona, Vaccarin 2022; 14
Ascierto, Dummer, Gogas 2020; 126
Weiss, Yaeger, Johnson 2021; 32
Echle, Ghaffari Laleh, Quirke 2022; 7
Jiang, Wang, Wang 2021; 10
Antoniotti, Rossini, Pietrantonio 2022; 23
Vaddavalli, Schumacher 2022; 38
Ros, Saoudi, Salvà 2022; 31
bibr82-15330338231178403
bibr112-15330338231178403
Ottaiano A (bibr122-15330338231178403) 2021; 11
Vargas JE (bibr182-15330338231178403) 2020; 2020
Wulaningsih W (bibr67-15330338231178403) 2016; 2
bibr27-15330338231178403
bibr54-15330338231178403
bibr165-15330338231178403
bibr138-15330338231178403
bibr140-15330338231178403
bibr166-15330338231178403
bibr28-15330338231178403
bibr193-15330338231178403
Safarzadeh E (bibr179-15330338231178403) 2014; 4
bibr56-15330338231178403
bibr136-15330338231178403
Qari W (bibr2-15330338231178403) 2022; 14
bibr110-15330338231178403
bibr81-15330338231178403
bibr192-15330338231178403
bibr137-15330338231178403
bibr80-15330338231178403
bibr167-15330338231178403
bibr191-15330338231178403
Nguyen HT (bibr33-15330338231178403) 2018; 16
Rodriguez M. (bibr131-15330338231178403) 2013; 4
bibr26-15330338231178403
bibr111-15330338231178403
bibr141-15330338231178403
bibr30-15330338231178403
bibr190-15330338231178403
bibr168-15330338231178403
bibr24-15330338231178403
bibr170-15330338231178403
Huang Z (bibr173-15330338231178403) 2022; 12
bibr115-15330338231178403
bibr188-15330338231178403
bibr77-15330338231178403
bibr135-15330338231178403
bibr57-15330338231178403
bibr32-15330338231178403
bibr108-15330338231178403
bibr163-15330338231178403
Weiss J (bibr150-15330338231178403) 2021; 32
bibr52-15330338231178403
bibr143-15330338231178403
El-Deiry WS (bibr133-15330338231178403) 2019; 9
bibr113-15330338231178403
bibr79-15330338231178403
bibr59-15330338231178403
bibr84-15330338231178403
bibr29-15330338231178403
bibr195-15330338231178403
Tarighati E (bibr14-15330338231178403) 2022; 23
bibr158-15330338231178403
bibr118-15330338231178403
Garcia FA de O (bibr18-15330338231178403) 2022; 12
bibr47-15330338231178403
bibr160-15330338231178403
Patel A (bibr132-15330338231178403) 2014; 8
bibr161-15330338231178403
bibr171-15330338231178403
bibr76-15330338231178403
bibr187-15330338231178403
Sara JD (bibr64-15330338231178403) 2018; 10
bibr86-15330338231178403
bibr120-15330338231178403
bibr87-15330338231178403
bibr147-15330338231178403
bibr157-15330338231178403
bibr10-15330338231178403
bibr60-15330338231178403
bibr107-15330338231178403
bibr46-15330338231178403
bibr117-15330338231178403
bibr20-15330338231178403
bibr50-15330338231178403
bibr7-15330338231178403
Daisy Precilla S (bibr90-15330338231178403) 2022; 95
bibr53-15330338231178403
bibr174-15330338231178403
bibr63-15330338231178403
bibr164-15330338231178403
bibr194-15330338231178403
Delibegovic S (bibr55-15330338231178403) 2017; 71
Amerizadeh F (bibr93-15330338231178403) 2022; 77
bibr124-15330338231178403
bibr23-15330338231178403
Gul S (bibr43-15330338231178403) 2022; 3
bibr73-15330338231178403
bibr154-15330338231178403
bibr134-15330338231178403
bibr114-15330338231178403
bibr13-15330338231178403
bibr104-15330338231178403
bibr180-15330338231178403
bibr4-15330338231178403
bibr152-15330338231178403
bibr125-15330338231178403
bibr41-15330338231178403
bibr178-15330338231178403
bibr153-15330338231178403
bibr68-15330338231178403
bibr42-15330338231178403
bibr5-15330338231178403
bibr66-15330338231178403
bibr126-15330338231178403
bibr15-15330338231178403
bibr96-15330338231178403
bibr100-15330338231178403
Narayan S (bibr6-15330338231178403) 2018
bibr71-15330338231178403
bibr16-15330338231178403
bibr101-15330338231178403
bibr97-15330338231178403
bibr127-15330338231178403
bibr70-15330338231178403
bibr181-15330338231178403
Nistal E (bibr49-15330338231178403) 2015; 5
bibr151-15330338231178403
bibr40-15330338231178403
bibr37-15330338231178403
bibr92-15330338231178403
bibr1-15330338231178403
bibr72-15330338231178403
bibr175-15330338231178403
bibr44-15330338231178403
bibr148-15330338231178403
bibr17-15330338231178403
De’ Angelis GL (bibr36-15330338231178403) 2018; 89
bibr128-15330338231178403
bibr155-15330338231178403
Wang C-J (bibr74-15330338231178403) 2019; 18
bibr130-15330338231178403
bibr12-15330338231178403
bibr183-15330338231178403
bibr89-15330338231178403
bibr69-15330338231178403
bibr99-15330338231178403
bibr8-15330338231178403
bibr123-15330338231178403
bibr94-15330338231178403
Lisi L (bibr144-15330338231178403) 2022; 175
bibr19-15330338231178403
bibr39-15330338231178403
bibr3-15330338231178403
bibr145-15330338231178403
bibr21-15330338231178403
bibr62-15330338231178403
bibr105-15330338231178403
bibr34-15330338231178403
bibr172-15330338231178403
bibr185-15330338231178403
bibr61-15330338231178403
bibr22-15330338231178403
bibr48-15330338231178403
bibr35-15330338231178403
Abraham SK (bibr184-15330338231178403) 2016; 31
bibr88-15330338231178403
bibr159-15330338231178403
bibr146-15330338231178403
bibr75-15330338231178403
bibr186-15330338231178403
Yang M (bibr103-15330338231178403) 2022; 146
bibr106-15330338231178403
bibr116-15330338231178403
Parmar S (bibr95-15330338231178403) 2022; 10
bibr91-15330338231178403
bibr11-15330338231178403
Huang J (bibr121-15330338231178403) 2022; 83
bibr31-15330338231178403
Cathomas G (bibr83-15330338231178403) 2014; 4
bibr102-15330338231178403
bibr162-15330338231178403
bibr142-15330338231178403
bibr45-15330338231178403
bibr176-15330338231178403
bibr58-15330338231178403
bibr156-15330338231178403
bibr25-15330338231178403
bibr38-15330338231178403
bibr65-15330338231178403
bibr149-15330338231178403
bibr85-15330338231178403
bibr78-15330338231178403
bibr169-15330338231178403
bibr98-15330338231178403
bibr189-15330338231178403
bibr129-15330338231178403
bibr139-15330338231178403
bibr119-15330338231178403
bibr109-15330338231178403
Yu IS (bibr177-15330338231178403) 2021; 19
bibr9-15330338231178403
Hou X (bibr51-15330338231178403) 2022; 13
References_xml – volume: 375
  start-page: 2255
  issue: 23
  year: 2016
  end-page: 2262
  article-title: T-Cell transfer therapy targeting mutant KRAS in cancer
  publication-title: N Engl J Med
– volume: 18
  start-page: 5301
  issue: 5
  year: 2019
  end-page: 5309
  article-title: Prognostic value of nuclear FBI-1 in patients with rectal cancer with or without preoperative radiotherapy
  publication-title: Oncol Lett
– volume: 90
  issue: 2
  year: 2022
  article-title: Optimized methods for analytical and functional comparison of biosimilar mAb drugs: A case study for Avastin, Mvasi, and Zirabev
  publication-title: Sci Pharm
– volume: 102
  start-page: 1101
  issue: 10
  year: 2022
  end-page: 1108
  article-title: Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer
  publication-title: Lab Investig
– volume: 11
  start-page: 10
  issue: September
  year: 2021
  end-page: 12
  article-title: Bevacizumab-Induced tumor vasculature normalization and sequential chemotherapy in colorectal cancer: An interesting and still open question
  publication-title: Front Oncol
– volume: 7
  start-page: 100400
  issue: 2
  year: 2022
  article-title: Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application
  publication-title: ESMO open
– volume: 12
  start-page: 3721
  issue: 1
  year: 2020
  end-page: 3729
  article-title: A second-line option for patients with hepatocellular carcinoma: A review of the evidence
  publication-title: Cancer Manag Res
– volume: 162
  start-page: 44
  issue: 1
  year: 2022
  end-page: 46
  article-title: STRAP: A Bridge Between Mutant APC and Wnt/ß-Catenin Signaling in Intestinal Cancer
  publication-title: Gastroenterology
– volume: 361
  start-page: 2449
  issue: 25
  year: 2009
  end-page: 2460
  article-title: Molecular origins of cancer: Molecular basis of colorectal cancer
  publication-title: N Engl J Med
– volume: 138
  start-page: 2044
  issue: 6
  year: 2010
  end-page: 2058
  article-title: Hereditary and familial colon cancer
  publication-title: Gastroenterology
– volume: 36
  start-page: 773
  issue: 8
  year: 2018
  end-page: 779
  article-title: Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 135
  start-page: 1079
  issue: 4
  year: 2008
  end-page: 1099
  article-title: Genomic and epigenetic instability in colorectal cancer pathogenesis
  publication-title: Gastroenterology
– volume: 23
  issue: 16
  year: 2022
  article-title: From dukes-MAC staging system to molecular classification: evolving concepts in colorectal cancer
  publication-title: Int J Mol Sci
– volume: 114
  start-page: 30
  issue: 1
  year: 2016
  end-page: 36
  article-title: Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
  publication-title: Br J Cancer
– volume: 29
  start-page: 3435
  issue: 11
  year: 2019
  end-page: 3447.e4
  article-title: A tumor-specific super-enhancer drives immune evasion by guiding synchronous expression of PD-L1 and PD-L2
  publication-title: Cell Rep
– volume: 14
  start-page: 83
  issue: 1
  year: 2019
  end-page: 103
  article-title: Insights into pathogenic interactions among environment, host, and tumor at the crossroads of molecular pathology and epidemiology
  publication-title: Annu Rev Pathol Mech Dis
– volume: 434
  start-page: 167256
  issue: 3
  year: 2022
  article-title: Studying the role of chromosomal instability (CIN) in GI cancers using patient-derived organoids
  publication-title: J Mol Biol
– volume: 10
  issue: 2
  year: 2018
  article-title: Colorectal cancer and alcohol consumption-populations to molecules
  publication-title: Cancers (Basel)
– volume: 15
  start-page: 305
  issue: 3
  year: 2007
  end-page: 309
  article-title: Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma
  publication-title: Appl Immunohistochem Mol Morphol AIMM
– volume: 30
  start-page: 124
  issue: 1
  year: 2019
  end-page: 131
  article-title: Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study
  publication-title: Ann Oncol Off J Eur Soc Med Oncol
– volume: 22
  start-page: 138
  issue: 1
  year: 2023
  end-page: 151
  article-title: Multiomics of colorectal cancer organoids reveals putative mediators of cancer progression resulting from SMAD4 inactivation
  publication-title: J Proteome Res
– volume: 32
  issue: Supplement 5
  year: 2021
  article-title: LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (cetux) in patients (pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
  publication-title: Ann Oncol
– volume: 21
  start-page: 12
  issue: 1
  year: 2021
  end-page: 26
  article-title: A review on the role of nanosensors in detecting cellular miRNA expression in colorectal cancer
  publication-title: Endocrine, Metabolic & Immune Disorders Drug Targets
– volume: 14
  issue: 9
  year: 2022
  article-title: Biomarkers of response and resistance to immunotherapy in microsatellite stable colorectal cancer: toward a new personalized medicine
  publication-title: Cancers (Basel)
– volume: 39
  start-page: 1143
  issue: 4
  year: 2020
  end-page: 1157
  article-title: Current therapy of advanced colorectal cancer according to RAS/RAF mutational status
  publication-title: Cancer Metastasis Rev
– volume: 130
  start-page: e301
  issue: 5
  year: 2020
  end-page: e307
  article-title: Severe oral erosive lichenoid reaction to pembrolizumab therapy
  publication-title: Oral Surg Oral Med Oral Pathol Oral Radiol
– volume: 124
  start-page: 176
  issue: 1
  year: 2021
  end-page: 182
  article-title: Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +/- binimetinib or alpelisib
  publication-title: Br J Cancer
– volume: 44
  start-page: 609
  issue: 3
  year: 2016
  end-page: 621
  article-title: MAP Kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade
  publication-title: Immunity
– volume: 8
  start-page: 42198
  issue: 26
  year: 2017
  end-page: 42213
  article-title: Molecular profiling of metastatic colorectal tumors using next-generation sequencing: A single-institution experience
  publication-title: Oncotarget
– volume: 42
  start-page: 8
  issue: 1
  year: 2023
  article-title: Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction.
  publication-title: J Exp & Clin Cancer Res CR
– volume: 14
  start-page: e30593
  issue: 10
  year: 2022
  article-title: Bilateral Wilms’ tumor with different responses to preoperative chemotherapy
  publication-title: Cureus
– volume: 13
  issue: 1
  year: 2022
  article-title: Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
  publication-title: Front Immunol
– volume: 146
  issue: 1
  year: 2022
  article-title: A multi-omics machine learning framework in predicting the survival of colorectal cancer patients
  publication-title: Comput Biol Med
– volume: 12
  start-page: 1
  issue: 1
  year: 2022
  end-page: 16
  article-title: Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells
  publication-title: Sci Rep
– volume: 35
  start-page: 2624
  issue: 23
  year: 2017
  end-page: 2630
  article-title: (Non-V600) BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 14
  issue: 7
  year: 2022
  article-title: Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies
  publication-title: Cancers (Basel)
– volume: 3
  start-page: 35
  issue: 1
  year: 2022
  end-page: 42
  article-title: Highlight DNA methylation biomarkers in different cancer types for drug designing
  publication-title: Journal of Epigenetics
– volume: 25
  start-page: 7089
  issue: 23
  year: 2019
  end-page: 7097
  article-title: Response to anti-EGFR therapy in patients with BRAF non-V600-mutant metastatic colorectal cancer
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
– volume: 5
  start-page: 236
  issue: 2
  year: 2019
  end-page: 242
  article-title: Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer
  publication-title: JAMA Oncol
– volume: 42
  start-page: 233
  issue: 1
  year: 2022
  end-page: 241
  article-title: Immune checkpoint blockade therapy in patients with colorectal cancer harboring microsatellite instability/mismatch repair deficiency in 2022
  publication-title: Am Soc Clin Oncol Educ B
– volume: 10
  issue: 1
  year: 2022
  article-title: Genetic and epigenetic dependencies in colorectal cancer development
  publication-title: Gastroenterol Rep
– volume: 15
  start-page: 747
  issue: 1
  year: 2022
  end-page: 756
  article-title: Targeting KRAS (G12C)-mutated advanced colorectal cancer: Research and clinical developments
  publication-title: Onco Targets Ther
– volume: 39
  start-page: 642
  issue: 6
  year: 2021
  end-page: 651
  article-title: Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: An ACCENT pooled analysis of 12 adjuvant trials
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 23
  start-page: 1
  issue: 13
  year: 2022
  end-page: 13
  article-title: The utilization of bevacizumab in patients with advanced ovarian cancer: A systematic review of the mechanisms and effects
  publication-title: Int J Mol Sci
– volume: 126
  start-page: 33
  issue: 1
  year: 2020
  end-page: 44
  article-title: Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
  publication-title: Eur J Cancer
– volume: 19
  start-page: 245
  issue: 1
  year: 2021
  article-title: Translational precision medicine: An industry perspective
  publication-title: J Transl Med
– volume: 26
  start-page: 126
  issue: 1
  year: 2015
  end-page: 132
  article-title: Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: Results of the PETACC-3 trial
  publication-title: Ann Oncol Off J Eur Soc Med Oncol
– volume: 244
  start-page: 217
  issue: 4901
  year: 1989
  end-page: 221
  article-title: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
  publication-title: Science
– volume: 10
  issue: 4
  year: 2020
  article-title: Predictive role of biopsy based biomarkers for radiotherapy treatment in rectal cancer
  publication-title: J Pers Med
– volume: 455
  start-page: 35
  issue: 1-2
  year: 2014
  end-page: 42
  article-title: Biological significance of the CpG island methylator phenotype
  publication-title: Biochem Biophys Res Commun
– volume: 6
  start-page: 28
  issue: 4
  year: 2014
  article-title: Personalised medicine in the UK: Challenges of implementation and impact on healthcare system
  publication-title: Genome Med
– volume: 49
  start-page: 941
  issue: 5
  year: 2022
  end-page: 949
  article-title: Oncologic outcomes of surgically managed primary pelvic soft tissue sarcoma; tumour biology or surgical constraints of the true pelvis?
  publication-title: Eur J Surg Oncol
– volume: 20
  start-page: 2919
  issue: 12
  year: 2019
  article-title: Chromogranin-A expression as a novel biomarker for early diagnosis of colon cancer patients
  publication-title: Int J Mol Sci
– volume: 10
  start-page: 1
  issue: 1
  year: 2018
  end-page: 18
  article-title: 5-fluorouracil And cardiotoxicity: A review
  publication-title: Ther Adv Med Oncol
– volume: 28
  start-page: 958
  issue: 5
  year: 2017
  end-page: 968
  article-title: Subgroups and prognostication in stage III colon cancer: Future perspectives for adjuvant therapy
  publication-title: Ann Oncol
– volume: 7
  start-page: 610
  issue: 6
  year: 2017
  end-page: 619
  article-title: A phase ib dose-escalation study of encorafenib and cetuximab with or without alpelisib in metastatic BRAF-mutant colorectal cancer
  publication-title: Cancer Discov
– volume: 11
  issue: 2
  year: 2021
  article-title: Precision medicine and public health: new challenges for effective and sustainable health
  publication-title: J Pers Med
– volume: 31
  start-page: 3664
  issue: 29
  year: 2013
  end-page: 3672
  article-title: Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 14
  start-page: 2664
  issue: 11
  year: 2022
  article-title: Loss of CHGA protein as a potential biomarker for colon cancer diagnosis: A study on biomarker discovery by machine learning and confirmation by immunohistochemistry in colorectal cancer tissue microarrays
  publication-title: Cancers (Basel)
– volume: 35
  start-page: 1497
  issue: 10
  year: 2018
  end-page: 1509
  article-title: An update of efficacy and safety of cetuximab in metastatic colorectal cancer: A narrative review
  publication-title: Adv Ther
– volume: 381
  start-page: 1632
  issue: 17
  year: 2019
  end-page: 1643
  article-title: Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer
  publication-title: N Engl J Med
– volume: 2020
  issue: Special Issue
  year: 2020
  article-title: Cellular mechanisms triggered by the cotreatment of resveratrol and doxorubicin in breast cancer: A translational in vitro-in silico model
  publication-title: Oxid Med Cell Longev
– volume: 5
  start-page: pbac005
  issue: 1
  year: 2022
  article-title: Novel directions of precision oncology: Circulating microbial DNA emerging in cancer-microbiome areas
  publication-title: Precis Clin Med
– volume: 349
  start-page: 247
  issue: 3
  year: 2003
  end-page: 257
  article-title: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
  publication-title: N Engl J Med
– volume: 10
  start-page: 1215
  issue: 6
  year: 2019
  end-page: 1221
  article-title: Complete mesocolic excision for colon cancer: Is it worth it?
  publication-title: J Gastrointest Oncol
– volume: 158
  start-page: 291
  issue: 2
  year: 2020
  end-page: 302
  article-title: Pathways of colorectal carcinogenesis
  publication-title: Gastroenterology
– volume: 37
  start-page: 337
  issue: 2
  year: 2022
  end-page: 348
  article-title: Comparison of safety and efficacy of fluorouracil + oxaliplatin + irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: Data from clinical practice
  publication-title: Int J Colorectal Dis
– volume: 18
  start-page: 18
  issue: 1
  year: 2011
  end-page: 25
  article-title: Oxaliplatin: A review in the era of molecularly targeted therapy
  publication-title: Curr Oncol
– volume: 41
  start-page: 107
  issue: 2
  year: 2005
  end-page: 127
  article-title: Cetuximab: An epidermal growth factor receptor chemeric human-murine monoclonal antibody
  publication-title: Drugs Today (Barc)
– volume: 54
  start-page: 475
  issue: 5
  year: 2022
  end-page: 485
  article-title: Endoscopic full-thickness resection of T1 colorectal cancers: A retrospective analysis from a multicenter Dutch eFTR registry
  publication-title: Endoscopy
– volume: 14
  start-page: 1
  issue: 12
  year: 2022
  end-page: 17
  article-title: Association of HLA-G 3′UTR polymorphisms with response to first-line FOLFIRI treatment in metastatic colorectal cancer
  publication-title: Pharmaceutics
– volume: 21
  start-page: 297
  issue: 1
  year: 2021
  article-title: Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: A systematic review and meta-analysis
  publication-title: BMC Gastroenterol
– volume: 13
  start-page: 6363
  issue: 24
  year: 2021
  article-title: Blood bacterial DNA load and profiling differ in colorectal cancer patients compared to tumor-free controls
  publication-title: Cancers (Basel)
– volume: 14
  issue: 15
  year: 2022
  article-title: Preliminary discovery of small molecule inhibitors of epidermal growth factor receptor (EGFR) that bind to the extracellular domain
  publication-title: Cancers (Basel)
– volume: 107
  start-page: 601
  issue: 5
  year: 2016
  end-page: 608
  article-title: Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma
  publication-title: Cancer Sci
– volume: 14
  issue: 11
  year: 2021
  article-title: A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine
  publication-title: Pharmaceuticals (Basel)
– volume: 12
  issue: 1
  year: 2022
  article-title: Molecular network of colorectal cancer and current therapeutic options
  publication-title: Front Oncol
– volume: 5
  start-page: 663
  issue: 4
  year: 2014
  end-page: 670
  article-title: Differential protective effects of red wine polyphenol extracts (RWEs) on colon carcinogenesis
  publication-title: Food Funct
– volume: 23
  start-page: 1
  issue: 1
  year: 2022
  end-page: 16
  article-title: A review of prognostic and predictive biomarkers in breast cancer
  publication-title: Clin Exp Med
– volume: 5
  issue: 1
  year: 2020
  article-title: Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study
  publication-title: ESMO open
– volume: 61
  start-page: 759
  issue: 5
  year: 1990
  end-page: 767
  article-title: A genetic model for colorectal tumorigenesis
  publication-title: Cell
– volume: 9
  start-page: 7739
  issue: 7
  year: 2018
  end-page: 7748
  article-title: Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
  publication-title: Oncotarget
– volume: 10
  start-page: 766
  issue: 11
  year: 2014
  article-title: Potential of fecal microbiota for early-stage detection of colorectal cancer
  publication-title: Mol Syst Biol
– volume: 39
  start-page: 273
  issue: 4
  year: 2021
  end-page: 284
  article-title: Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 81
  start-page: 849
  issue: 7
  year: 2021
  end-page: 856
  article-title: Encorafenib: A review in metastatic colorectal cancer with a BRAF V600E mutation
  publication-title: Drugs
– volume: 83
  issue: 1
  year: 2022
  article-title: Effects of microbiota on anticancer drugs: Current knowledge and potential applications
  publication-title: eBioMedicine
– volume: 12
  start-page: 502
  issue: 3
  year: 2019
  end-page: 512
  article-title: Oncologic outcomes in metastatic colorectal cancer with regorafenib with FOLFIRI as a third- or fourth-line setting
  publication-title: Transl Oncol
– volume: 5
  issue: 1
  year: 2015
  article-title: Factors determining colorectal cancer: The role of the intestinal microbiota
  publication-title: Front Oncol
– volume: 18
  issue: 1
  year: 2017
  article-title: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer
  publication-title: Int J Mol Sci
– volume: 257
  start-page: 39
  issue: 1
  year: 2022
  end-page: 52
  article-title: Characterization of RNF43 frameshift mutations that drive Wnt ligand- and R-spondin-dependent colon cancer
  publication-title: J Pathol
– volume: 169
  start-page: 103537
  issue: 1
  year: 2022
  article-title: Adjuvant treatment of colon cancer with microsatellite instability – the state of the art
  publication-title: Crit Rev Oncol Hematol
– volume: 4
  start-page: 16
  issue: March
  year: 2014
  end-page: 19
  article-title: PIK3CA In colorectal cancer
  publication-title: Front Oncol.
– volume: 23
  start-page: 1
  issue: 6
  year: 2022
  end-page: 12
  article-title: The complete loss of p53 expression uniquely predicts worse prognosis in colorectal cancer
  publication-title: Int J Mol Sci
– volume: 35
  start-page: 141
  issue: 02
  year: 2022
  end-page: 145
  article-title: Limitations and concerns with transanal total mesorectal excision for rectal cancer
  publication-title: Clin Colon Rectal Surg
– volume: 8
  start-page: 13
  issue: 1
  year: 2014
  end-page: 25
  article-title: Ziv-aflibercept in metastatic colorectal cancer
  publication-title: Biologics
– volume: 17
  issue: 3
  year: 2022
  article-title: Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors
  publication-title: PLOS ONE
– volume: 71
  start-page: 209
  issue: 3
  year: 2021
  end-page: 249
  article-title: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J Clin
– volume: 130
  start-page: 202
  issue: 3
  year: 2022
  end-page: 214
  article-title: Evaluation and diagnostic value of next-generation sequencing analysis of residual liquid-based cytology specimens of pancreatic masses
  publication-title: Cancer Cytopathol
– volume: 383
  start-page: 2207
  issue: 23
  year: 2020
  end-page: 2218
  article-title: Pembrolizumab in microsatellite-instability-high advanced colorectal cancer
  publication-title: N Engl J Med
– volume: 20
  start-page: 3
  issue: 1
  year: 2020
  end-page: 18
  article-title: Anti-VEGF/VEGFR2 monoclonal antibodies and their combinations with PD-1/PD-L1 inhibitors in clinic
  publication-title: Curr Cancer Drug Targets
– volume: 11
  start-page: 1
  issue: 1
  year: 2022
  end-page: 14
  article-title: Engineering an enhanced EGFR engager: Humanization of cetuximab for improved developability
  publication-title: Antibodies
– volume: 149
  start-page: 728
  issue: 3
  year: 2021
  end-page: 740
  article-title: Feasibility of deep learning-based fully automated classification of microsatellite instability in tissue slides of colorectal cancer
  publication-title: Int J Cancer
– volume: 72
  start-page: 2457
  issue: 10
  year: 2012
  end-page: 2467
  article-title: A comprehensive survey of Ras mutations in cancer
  publication-title: Cancer Res
– volume: 8
  start-page: 50284
  issue: 30
  year: 2017
  end-page: 50304
  article-title: Integration of phytochemicals and phytotherapy into cancer precision medicine
  publication-title: Oncotarget
– volume: 12
  start-page: 13131
  issue: 1
  year: 2022
  article-title: Curcumin piperidone derivatives induce anti-proliferative and anti-migratory effects in LN-18 human glioblastoma cells
  publication-title: Sci Rep
– volume: 36
  start-page: 3374
  issue: 5
  year: 2022
  end-page: 3381
  article-title: Long-term oncological outcomes after laparoscopic parenchyma-sparing redo liver resections for patients with metastatic colorectal cancer: A European multi-center study
  publication-title: Surg Endosc
– volume: 12
  start-page: 1
  issue: 1
  year: 2022
  end-page: 11
  article-title: New insights on familial colorectal cancer type X syndrome
  publication-title: Sci Rep
– volume: 27
  issue: 6
  year: 2022
  article-title: The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases
  publication-title: Front Biosci - Landmark
– volume: 20
  start-page: 3472
  issue: 13
  year: 2014
  end-page: 3484
  article-title: Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
– volume: 33
  start-page: 4023
  issue: 34
  year: 2015
  end-page: 4031
  article-title: Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 158
  start-page: 487
  issue: 6
  year: 2021
  end-page: 496
  article-title: Therapeutic implications of B-RAF mutations in colorectal cancer
  publication-title: J Visc Surg
– volume: 2
  start-page: CD008593
  issue: 2
  year: 2016
  article-title: Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer
  publication-title: Cochrane Database Syst Rev
– volume: 383
  start-page: 1207
  issue: 13
  year: 2020
  end-page: 1217
  article-title: KRAS(G12c) inhibition with sotorasib in advanced solid tumors
  publication-title: N Engl J Med
– volume: 4
  start-page: 421
  issue: Suppl 1
  year: 2014
  end-page: 427
  article-title: Herbal medicine as inducers of apoptosis in cancer treatment
  publication-title: Adv Pharm Bull
– volume: 10
  start-page: 6823
  issue: 19
  year: 2021
  end-page: 6834
  article-title: ITGB4 As a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer
  publication-title: Cancer Med
– volume: 3
  start-page: 502
  issue: 5
  year: 2013
  end-page: 511
  article-title: Molecular dissection of microsatellite instable colorectal cancer
  publication-title: Cancer Discov
– volume: 62
  start-page: 455
  issue: 1
  year: 2022
  end-page: 464
  article-title: Association of prebiotic fiber intake with colorectal cancer risk: The PrebiotiCa study
  publication-title: Eur J Nutr
– volume: 39
  start-page: 5152
  issue: 28
  year: 2020
  end-page: 5164
  article-title: Integrative multi-omics analysis of a colon cancer cell line with heterogeneous Wnt activity revealed RUNX2 as an epigenetic regulator of EMT
  publication-title: Oncogene
– volume: 59
  start-page: 685
  issue: 4
  year: 2023
  article-title: An updated review on the role of nanoformulated phytochemicals in colorectal cancer
  publication-title: Medicina (B Aires)
– volume: 71
  start-page: 434
  issue: 6
  year: 2017
  end-page: 438
  article-title: Introduction to total mesorectal excision
  publication-title: Med Arch (Sarajevo, Bosnia Herzegovina)
– volume: 29
  start-page: 921
  issue: 5
  year: 2022
  end-page: 937
  article-title: Structural diversity of p63 and p73 isoforms
  publication-title: Cell Death Differ.
– volume: 31
  start-page: 235
  issue: 3
  year: 2022
  end-page: 247
  article-title: Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies
  publication-title: Expert Opin Investig Drugs
– volume: 31
  start-page: 27
  issue: 1
  year: 2016
  end-page: 33
  article-title: Antigenotoxic effects of resveratrol: Assessment of in vitro and in vivo response
  publication-title: Mutagenesis
– volume: 63
  start-page: 103753
  issue: 3
  year: 2020
  article-title: The spectrum of Lynch syndrome-associated germ-line mutations in Russia
  publication-title: Eur J Med Genet
– volume: 12
  start-page: 138
  issue: 1
  year: 2023
  article-title: The cytokine network in colorectal cancer: Implications for new treatment strategies
  publication-title: Cells
– volume: 13
  start-page: 1187
  issue: 8
  year: 2013
  end-page: 1196
  article-title: Targeted inhibition of VEGF receptor 2: An update on ramucirumab
  publication-title: Expert Opin Biol Ther
– volume: 13
  start-page: 1
  issue: 1
  year: 2020
  end-page: 10
  article-title: Colon cancer: A clinician’s perspective in 2019
  publication-title: Gastroenterol Res
– volume: 4
  start-page: 348
  issue: 5
  year: 2013
  end-page: 352
  article-title: Ziv-aflibercept use in metastatic colorectal cancer
  publication-title: J Adv Pract Oncol
– volume: 12
  issue: 4
  year: 2020
  article-title: The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis
  publication-title: Cancers (Basel)
– volume: 95
  issue: 1
  year: 2022
  article-title: Crosstalk between PI3 K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
  publication-title: Cell Signal
– volume: 27
  start-page: 1386
  issue: 8
  year: 2016
  end-page: 1422
  article-title: ESMO Consensus guidelines for the management of patients with metastatic colorectal cancer
  publication-title: Ann Oncol Off J Eur Soc Med Oncol
– volume: 14
  start-page: 378
  issue: 3
  year: 2008
  end-page: 389
  article-title: Cancer in inflammatory bowel disease
  publication-title: World J Gastroenterol
– volume: 1878
  start-page: 188827
  issue: 1
  year: 2023
  article-title: EGFR Pathway targeting drugs in head and neck cancer in the era of immunotherapy
  publication-title: Biochim Biophys Acta - Rev Cancer
– volume: 25
  start-page: 1673
  issue: 9
  year: 2014
  end-page: 1678
  article-title: Delivering precision medicine in oncology today and in future-the promise and challenges of personalised cancer medicine: A position paper by the European Society for Medical Oncology (ESMO)
  publication-title: Ann Oncol Off J Eur Soc Med Oncol
– volume: 33
  start-page: 4032
  issue: 34
  year: 2015
  end-page: 4038
  article-title: Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 37
  start-page: e99
  issue: 4
  year: 2013
  end-page: 101
  article-title: Full thickness endoscopic resection of a colonic cancer: A case report
  publication-title: Clin Res Hepatol Gastroenterol
– volume: 14
  issue: 4
  year: 2022
  article-title: Comprehensive analysis of nivolumab, a therapeutic anti-Pd-1 monoclonal antibody: impact of handling and stress
  publication-title: Pharmaceutics
– volume: 12
  start-page: 2219
  issue: 9
  year: 2016
  end-page: 2231
  article-title: Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
  publication-title: Hum Vaccin Immunother
– volume: 60
  start-page: 397
  issue: 3
  year: 2011
  end-page: 411
  article-title: Molecular pathological epidemiology of colorectal neoplasia: An emerging transdisciplinary and interdisciplinary field
  publication-title: Gut
– volume: 175
  issue: 1
  year: 2022
  article-title: Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
  publication-title: Pharmacol Res
– volume: 19
  start-page: 774
  issue: 12
  year: 2021
  end-page: 783
  article-title: The emergence of targetable pathways in colorectal cancer
  publication-title: Clin Adv Hematol Oncol
– volume: 12
  issue: 9
  year: 2020
  article-title: Adjuvant chemotherapy for stage III colon cancer
  publication-title: Cancers (Basel)
– volume: 2
  start-page: 293
  issue: 3
  year: 2016
  end-page: 294
  article-title: Precision medicine and low- to middle-income countries
  publication-title: JAMA Oncol
– volume: 2
  start-page: 1
  issue: 1
  year: 2012
  end-page: 14
  article-title: Personalized medicine and cancer
  publication-title: J Pers Med
– volume: 23
  issue: 16
  year: 2022
  article-title: Role of the WNT/β-catenin/ZKSCAN3 pathway in regulating chromosomal instability in colon cancer cell lines and tissues
  publication-title: Int J Mol Sci
– volume: 12
  start-page: 50
  issue: 2-3
  year: 2021
  end-page: 60
  article-title: Personalized medicine in oncology in the developing world: Barriers and concepts to improve Status quo
  publication-title: World J Oncol
– volume: 6
  start-page: 44758
  issue: 42
  year: 2015
  end-page: 44780
  article-title: Radiation and SN38 treatments modulate the expression of microRNAs, cytokines and chemokines in colon cancer cells in a p53-directed manner
  publication-title: Oncotarget
– volume: 86
  start-page: 748
  issue: Pt 2
  year: 2022
  end-page: 768
  article-title: RNA-binding proteins and cancer metastasis
  publication-title: Semin Cancer Biol
– volume: 16
  start-page: 9
  issue: 1
  year: 2018
  end-page: 18
  article-title: The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (review)
  publication-title: Oncol Lett
– volume: 12
  start-page: 1702
  issue: 7
  year: 2022
  end-page: 1717
  article-title: Synthetic essentiality of tryptophan 2, 3-dioxygenase 2 in APC-mutated colorectal cancer
  publication-title: Cancer Discov
– volume: 77
  issue: 1
  year: 2022
  article-title: Inhibition of the Wnt/b-catenin pathway using PNU-74654 reduces tumor growth in in vitro and in vivo models of colorectal cancer
  publication-title: Tissue Cell
– volume: 21
  start-page: 1313
  issue: 6
  year: 2015
  end-page: 1320
  article-title: Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients
  publication-title: Clin Cancer Res an Off J Am Assoc Cancer Res
– volume: 9
  start-page: 1
  issue: MAR
  year: 2019
  end-page: 13
  article-title: Disease control with FOLFIRI plus Ziv-aflibercept (zFOLFIRI) beyond FOLFIRI plus bevacizumab: Case series in metastatic colorectal cancer (mCRC)
  publication-title: Front Oncol
– volume: 54
  start-page: 156
  issue: 2
  year: 2022
  end-page: 168
  article-title: Hypermethylation of PDX1, EN2, and MSX1 predicts the prognosis of colorectal cancer
  publication-title: Exp Mol Med
– volume: 22
  issue: 1
  year: 2020
  article-title: Molecular mechanisms of colon cancer progression and metastasis: recent insights and advancements
  publication-title: Int J Mol Sci
– volume: 29
  start-page: 2644
  issue: 4
  year: 2022
  end-page: 2649
  article-title: 5-Fluorouracil/L-Leucovorin Plus oxaliplatin (FOLFOX) regimen as salvage chemotherapy for patients with unresectable pancreatic cancer receiving gemcitabine and nab-paclitaxel and 5-fluorouracil/L-leucovorin plus nanoliposomal irinotecan: Preliminary resu
  publication-title: Curr Oncol
– volume: 23
  start-page: 876
  issue: 7
  year: 2022
  end-page: 887
  article-title: Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): A multicentre, open-label, randomised, controlled, phase 2 trial
  publication-title: Lancet Oncol
– volume: 96
  start-page: 8681
  issue: 15
  year: 1999
  end-page: 8686
  article-title: Cpg island methylator phenotype in colorectal cancer
  publication-title: Proc Natl Acad Sci U S A
– volume: 94
  start-page: 79
  issue: 1
  year: 2018
  end-page: 87
  article-title: Significant expression of tafazzin (TAZ) protein in colon cancer cells and its downregulation by radiation
  publication-title: Int J Radiat Biol
– volume: 37
  start-page: 1411
  issue: 8
  year: 2022
  end-page: 1425
  article-title: The emerging era of personalized medicine in advanced colorectal cancer
  publication-title: J Gastroenterol Hepatol
– volume: 268
  start-page: 1336
  issue: 5215
  year: 1995
  end-page: 1338
  article-title: Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
  publication-title: Science
– volume: 16
  start-page: 161
  issue: 2
  year: 2015
  end-page: 168
  article-title: Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: A retrospective, population-based study
  publication-title: Lancet Oncol
– volume: 18
  start-page: 570
  issue: 2
  year: 2023
  end-page: 584
  article-title: USP7 Inactivation suppresses APC-mutant intestinal hyperproliferation and tumor development
  publication-title: Stem Cell Rep.
– volume: 22
  start-page: 1
  issue: 1
  year: 2022
  end-page: 11
  article-title: Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: Study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)
  publication-title: BMC Cancer
– volume: 10
  start-page: 6623
  issue: 61
  year: 2019
  end-page: 6640
  article-title: The multifaceted anti-cancer effects of BRAF-inhibitors
  publication-title: Oncotarget
– volume: 23
  start-page: 1517
  issue: 5
  year: 2022
  end-page: 1522
  article-title: The mutation Spectrum and two novel point mutations in the APC gene in Vietnamese patients with familial adenomatous polyposis
  publication-title: Asian Pac J Cancer Prev.
– volume: 304
  start-page: 554
  issue: 5670
  year: 2004
  article-title: High frequency of mutations of the PIK3CA gene in human cancers
  publication-title: Science
– volume: 29
  start-page: 1261
  issue: 10
  year: 2011
  end-page: 1270
  article-title: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer
  publication-title: J Clin Oncol Off J Am Soc Clin Oncol
– volume: 11
  issue: 2
  year: 2019
  article-title: Potential applications of DNA, RNA and protein biomarkers in diagnosis, therapy and prognosis for colorectal cancer: a study from databases to AI-assisted verification
  publication-title: Cancers (Basel)
– volume: 12
  start-page: 150
  issue: 1
  year: 2016
  end-page: 156
  article-title: A comparison of four methods for detecting KRAS mutations in formalin-fixed specimens from metastatic colorectal cancer patients
  publication-title: Oncol Lett
– volume: 149
  start-page: 1177
  issue: 5
  year: 2015
  end-page: 1190.e3
  article-title: Genetics and genetic biomarkers in sporadic colorectal cancer
  publication-title: Gastroenterology
– volume: 12
  start-page: 404
  issue: 3
  year: 2019
  end-page: 416
  article-title: Cyclical treatment of colorectal tumor spheroids induces resistance to MEK inhibitors
  publication-title: Transl Oncol
– volume: 98
  start-page: 102218
  issue: 1
  year: 2021
  article-title: Metastatic colorectal cancer: Advances in the folate-fluoropyrimidine chemotherapy backbone
  publication-title: Cancer Treat Rev
– volume: 63
  start-page: 797
  issue: 6
  year: 2019
  end-page: 811
  article-title: The DNA methylation landscape in cancer
  publication-title: Essays Biochem
– volume: 630
  start-page: 151
  issue: 1
  year: 2022
  end-page: 157
  article-title: Cell cycle expression of FLJ25439, a cytokinesis-associated protein, is mediated by D-box recognition and APC/C-Cdc20 regulated degradation
  publication-title: Biochem Biophys Res Commun
– volume: 119
  start-page: 9573
  issue: 11
  year: 2018
  end-page: 9582
  article-title: The dietary flavone luteolin epigenetically activates the Nrf2 pathway and blocks cell transformation in human colorectal cancer HCT116 cells
  publication-title: J Cell Biochem
– volume: 14
  start-page: 833
  issue: 4
  year: 2022
  end-page: 841
  article-title: Current guidelines in the surgical management of hereditary colorectal cancers
  publication-title: World J Gastrointest Oncol
– volume: 16
  start-page: 306
  issue: 1
  year: 2021
  article-title: A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations
  publication-title: Orphanet J Rare Dis
– volume: 29
  start-page: 44
  issue: 1
  year: 2018
  end-page: 70
  article-title: Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: A JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
  publication-title: Ann Oncol Off J Eur Soc Med Oncol
– volume: 89
  start-page: 97
  issue: 9-S
  year: 2018
  end-page: 101
  article-title: Microsatellite instability in colorectal cancer
  publication-title: Acta Biomed
– volume: 8
  start-page: 760
  issue: 5
  year: 2022
  end-page: 769
  article-title: Diagnosis and treatment of ERBB2-positive metastatic colorectal cancer: A review
  publication-title: JAMA Oncol
– volume: 1
  start-page: 1
  issue: 1
  year: 2022
  end-page: 13
  article-title: Colorectal cancer screening — approach, evidence, and future directions
  publication-title: NEJM Evid
– volume: 15
  start-page: 542
  issue: 3
  year: 2023
  article-title: Fabrication of sustained release curcumin-loaded solid lipid nanoparticles (cur-SLNs) as a potential drug delivery system for the treatment of lung cancer : Optimization of formulation and in vitro biological evaluation
  publication-title: Polymers (Basel)
– volume: 163
  start-page: 637
  issue: 3
  year: 2022
  end-page: 648.e2
  article-title: Association between metabolic syndrome and the risk of colorectal cancer diagnosed before age 50 years according to tumor location
  publication-title: Gastroenterology
– volume: 10
  issue: 5
  year: 2022
  article-title: Colorectal cancer heterogeneity and the impact on precision medicine and therapy efficacy
  publication-title: Biomedicines
– volume: 37
  start-page: 159
  issue: 1
  year: 2018
  end-page: 172
  article-title: Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: Implications for therapeutic targeting
  publication-title: Cancer Metastasis Rev
– volume: 38
  start-page: 598
  issue: 6
  year: 2022
  end-page: 612
  article-title: The p53 network: Cellular and systemic DNA damage responses in cancer and aging
  publication-title: Trends Genet
– volume: 21
  start-page: 509
  issue: 7
  year: 2022
  end-page: 528
  article-title: The foundations of immune checkpoint blockade and the ipilimumab approval decennial
  publication-title: Nat Rev Drug Discov
– volume: 12
  issue: 1
  year: 2022
  ident: bibr173-15330338231178403
  publication-title: Front Oncol
– ident: bibr61-15330338231178403
  doi: 10.1007/s00464-021-08655-z
– ident: bibr63-15330338231178403
  doi: 10.1016/j.ctrv.2021.102218
– volume: 13
  issue: 1
  year: 2022
  ident: bibr51-15330338231178403
  publication-title: Front Immunol
– ident: bibr194-15330338231178403
  doi: 10.3390/ph14111077
– ident: bibr25-15330338231178403
  doi: 10.1016/0092-8674(90)90186-I
– ident: bibr62-15330338231178403
  doi: 10.1016/j.ejso.2022.12.005
– ident: bibr59-15330338231178403
  doi: 10.1016/j.clinre.2012.10.005
– ident: bibr92-15330338231178403
  doi: 10.1053/j.gastro.2021.09.074
– ident: bibr138-15330338231178403
  doi: 10.1517/14712598.2013.810717
– ident: bibr155-15330338231178403
  doi: 10.1093/annonc/mdw235
– ident: bibr114-15330338231178403
  doi: 10.3892/ol.2016.4576
– ident: bibr42-15330338231178403
  doi: 10.1042/EBC20190037
– ident: bibr113-15330338231178403
  doi: 10.1002/cncy.22525
– ident: bibr98-15330338231178403
  doi: 10.1038/s41388-020-1351-z
– volume: 4
  start-page: 348
  issue: 5
  year: 2013
  ident: bibr131-15330338231178403
  publication-title: J Adv Pract Oncol
– ident: bibr8-15330338231178403
  doi: 10.3390/jpm2010001
– ident: bibr84-15330338231178403
  doi: 10.1126/science.2649981
– ident: bibr164-15330338231178403
  doi: 10.1200/JCO.20.02088
– volume: 175
  issue: 1
  year: 2022
  ident: bibr144-15330338231178403
  publication-title: Pharmacol Res
– ident: bibr191-15330338231178403
– volume: 146
  issue: 1
  year: 2022
  ident: bibr103-15330338231178403
  publication-title: Comput Biol Med
– ident: bibr186-15330338231178403
  doi: 10.14740/wjon1345
– ident: bibr77-15330338231178403
  doi: 10.18632/oncotarget.15030
– volume: 5
  issue: 1
  year: 2015
  ident: bibr49-15330338231178403
  publication-title: Front Oncol
– ident: bibr71-15330338231178403
  doi: 10.1080/09553002.2018.1400191
– ident: bibr172-15330338231178403
  doi: 10.1093/annonc/mdu499
– ident: bibr46-15330338231178403
  doi: 10.1016/j.bbrc.2014.07.007
– ident: bibr110-15330338231178403
  doi: 10.3390/cancers14112664
– ident: bibr23-15330338231178403
  doi: 10.1056/NEJMra0804588
– ident: bibr73-15330338231178403
  doi: 10.18632/oncotarget.5815
– ident: bibr76-15330338231178403
  doi: 10.3390/biomedicines10051035
– ident: bibr10-15330338231178403
  doi: 10.3390/cancers14092241
– ident: bibr175-15330338231178403
  doi: 10.1136/esmoopen-2019-000638
– ident: bibr60-15330338231178403
  doi: 10.31083/j.fbl2706189
– ident: bibr78-15330338231178403
  doi: 10.1016/j.jviscsurg.2021.04.002
– ident: bibr28-15330338231178403
  doi: 10.1016/j.jmb.2021.167256
– ident: bibr117-15330338231178403
  doi: 10.1007/s40265-021-01501-5
– ident: bibr125-15330338231178403
  doi: 10.3390/cancers14153647
– ident: bibr195-15330338231178403
  doi: 10.1093/annonc/mdu217
– ident: bibr112-15330338231178403
  doi: 10.1371/journal.pone.0264138
– ident: bibr32-15330338231178403
  doi: 10.3390/ijms18010197
– ident: bibr12-15330338231178403
  doi: 10.1001/jamaoncol.2021.8196
– ident: bibr129-15330338231178403
  doi: 10.1016/j.bbcan.2022.188827
– ident: bibr70-15330338231178403
  doi: 10.3390/curroncol29040216
– volume: 95
  issue: 1
  year: 2022
  ident: bibr90-15330338231178403
  publication-title: Cell Signal
– volume-title: Challenges and Future Opportunities of Nanomedicine in Cancer Therapy
  year: 2018
  ident: bibr6-15330338231178403
– volume: 8
  start-page: 13
  issue: 1
  year: 2014
  ident: bibr132-15330338231178403
  publication-title: Biologics
– ident: bibr15-15330338231178403
  doi: 10.1053/j.gastro.2015.06.047
– ident: bibr91-15330338231178403
  doi: 10.31557/APJCP.2022.23.5.1517
– ident: bibr139-15330338231178403
  doi: 10.1016/j.oooo.2020.06.014
– volume: 2020
  year: 2020
  ident: bibr182-15330338231178403
  publication-title: Oxid Med Cell Longev
  doi: 10.1155/2020/5432651
– ident: bibr4-15330338231178403
  doi: 10.2174/1871530320666200515115723
– ident: bibr190-15330338231178403
  doi: 10.3390/jpm11020135
– ident: bibr30-15330338231178403
  doi: 10.1007/s10555-017-9725-6
– ident: bibr72-15330338231178403
  doi: 10.3390/jpm10040168
– ident: bibr154-15330338231178403
  doi: 10.1093/annonc/mdx738
– ident: bibr130-15330338231178403
  doi: 10.1038/s41598-022-21582-w
– volume: 23
  start-page: 1
  issue: 1
  year: 2022
  ident: bibr14-15330338231178403
  publication-title: Clin Exp Med
– volume: 2
  start-page: CD008593
  issue: 2
  year: 2016
  ident: bibr67-15330338231178403
  publication-title: Cochrane Database Syst Rev
– ident: bibr35-15330338231178403
  doi: 10.3390/ijms23063252
– ident: bibr148-15330338231178403
  doi: 10.18632/oncotarget.22471
– volume: 11
  start-page: 10
  year: 2021
  ident: bibr122-15330338231178403
  publication-title: Front Oncol
– ident: bibr140-15330338231178403
  doi: 10.1016/j.celrep.2019.10.093
– volume: 83
  issue: 1
  year: 2022
  ident: bibr121-15330338231178403
  publication-title: eBioMedicine
– ident: bibr17-15330338231178403
  doi: 10.4251/wjgo.v14.i4.833
– ident: bibr145-15330338231178403
  doi: 10.1038/s41573-021-00345-8
– ident: bibr50-15330338231178403
  doi: 10.3390/cancers10020038
– ident: bibr136-15330338231178403
  doi: 10.1016/j.tranon.2018.12.003
– ident: bibr19-15330338231178403
  doi: 10.1007/s00394-022-02984-y
– ident: bibr180-15330338231178403
  doi: 10.1038/s41598-022-16274-4
– ident: bibr34-15330338231178403
  doi: 10.3390/cells12010138
– ident: bibr89-15330338231178403
  doi: 10.1158/2159-8290.CD-21-0680
– ident: bibr174-15330338231178403
  doi: 10.1200/JCO.2017.35.15_suppl.TPS3630
– ident: bibr105-15330338231178403
  doi: 10.3390/cancers13246363
– ident: bibr68-15330338231178403
  doi: 10.3390/pharmaceutics14122737
– ident: bibr106-15330338231178403
  doi: 10.1093/pcmedi/pbac005
– ident: bibr97-15330338231178403
  doi: 10.3390/ijms22010130
– volume: 31
  start-page: 27
  issue: 1
  year: 2016
  ident: bibr184-15330338231178403
  publication-title: Mutagenesis
– volume: 10
  start-page: 1
  issue: 1
  year: 2018
  ident: bibr64-15330338231178403
  publication-title: Ther Adv Med Oncol
– ident: bibr156-15330338231178403
  doi: 10.18632/oncotarget.27304
– ident: bibr193-15330338231178403
– volume: 12
  start-page: 1
  issue: 1
  year: 2022
  ident: bibr18-15330338231178403
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-99269-x
– volume: 14
  start-page: e30593
  issue: 10
  year: 2022
  ident: bibr2-15330338231178403
  publication-title: Cureus
– ident: bibr142-15330338231178403
  doi: 10.3390/pharmaceutics14040692
– ident: bibr115-15330338231178403
  doi: 10.1097/01.pai.0000213141.47277.bf
– ident: bibr79-15330338231178403
  doi: 10.1016/j.tranon.2018.11.009
– ident: bibr20-15330338231178403
  doi: 10.1053/j.gastro.2010.01.054
– ident: bibr166-15330338231178403
  doi: 10.1200/JCO.2015.63.2471
– ident: bibr101-15330338231178403
  doi: 10.1021/acs.jproteome.2c00551
– ident: bibr181-15330338231178403
  doi: 10.3390/polym15030542
– ident: bibr189-15330338231178403
  doi: 10.1186/gm545
– volume: 18
  start-page: 5301
  issue: 5
  year: 2019
  ident: bibr74-15330338231178403
  publication-title: Oncol Lett
– ident: bibr96-15330338231178403
  doi: 10.3322/caac.21660
– ident: bibr146-15330338231178403
  doi: 10.1016/j.ejca.2019.11.016
– ident: bibr54-15330338231178403
  doi: 10.1055/s-0041-1742115
– ident: bibr158-15330338231178403
  doi: 10.1200/JCO.2015.63.2497
– ident: bibr116-15330338231178403
  doi: 10.2147/OTT.S340392
– ident: bibr44-15330338231178403
  doi: 10.1053/j.gastro.2019.08.059
– ident: bibr126-15330338231178403
  doi: 10.1358/dot.2005.41.2.882662
– ident: bibr183-15330338231178403
  doi: 10.1039/c3fo60417a
– ident: bibr11-15330338231178403
  doi: 10.1111/jgh.15937
– ident: bibr143-15330338231178403
  doi: 10.1080/21645515.2016.1175694
– ident: bibr169-15330338231178403
  doi: 10.1056/NEJMoa022289
– ident: bibr111-15330338231178403
  doi: 10.1186/s12967-021-02910-6
– ident: bibr176-15330338231178403
  doi: 10.1200/JCO.2017.76.9901
– ident: bibr48-15330338231178403
  doi: 10.1007/978-981-16-4752-9_24
– ident: bibr153-15330338231178403
  doi: 10.1016/S1470-2045(22)00274-1
– ident: bibr170-15330338231178403
  doi: 10.1200/JCO.20.01600
– ident: bibr187-15330338231178403
  doi: 10.1001/jamaoncol.2018.5070
– volume: 4
  start-page: 16
  year: 2014
  ident: bibr83-15330338231178403
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2014.00035
– ident: bibr147-15330338231178403
  doi: 10.1007/s10555-020-09913-7
– ident: bibr165-15330338231178403
  doi: 10.1038/s41416-020-01147-2
– ident: bibr22-15330338231178403
  doi: 10.14740/gr1239
– ident: bibr82-15330338231178403
  doi: 10.1186/s13023-021-01929-8
– volume: 16
  start-page: 9
  issue: 1
  year: 2018
  ident: bibr33-15330338231178403
  publication-title: Oncol Lett
– ident: bibr65-15330338231178403
  doi: 10.3747/co.v18i1.708
– ident: bibr9-15330338231178403
  doi: 10.3390/medicina59040685
– ident: bibr124-15330338231178403
  doi: 10.3390/antib11010006
– ident: bibr31-15330338231178403
  doi: 10.3748/wjg.14.378
– ident: bibr171-15330338231178403
  doi: 10.1158/2159-8290.CD-12-0471
– ident: bibr135-15330338231178403
  doi: 10.1158/1078-0432.CCR-13-2944
– ident: bibr159-15330338231178403
  doi: 10.1093/annonc/mdy461
– ident: bibr109-15330338231178403
  doi: 10.1002/cam4.4216
– ident: bibr152-15330338231178403
  doi: 10.1056/NEJMoa1609279
– ident: bibr163-15330338231178403
  doi: 10.1158/1078-0432.CCR-19-2004
– ident: bibr94-15330338231178403
  doi: 10.1186/s12876-021-01864-9
– ident: bibr192-15330338231178403
  doi: 10.17265/2159-5313/2016.09.003
– ident: bibr75-15330338231178403
  doi: 10.1158/0008-5472.CAN-11-2612
– ident: bibr58-15330338231178403
  doi: 10.1055/a-1637-9051
– volume: 89
  start-page: 97
  issue: 9
  year: 2018
  ident: bibr36-15330338231178403
  publication-title: Acta Biomed
– ident: bibr27-15330338231178403
  doi: 10.1126/science.7761852
– ident: bibr107-15330338231178403
  doi: 10.3390/cancers11020172
– ident: bibr128-15330338231178403
– ident: bibr81-15330338231178403
  doi: 10.1200/JCO.2016.71.4394
– ident: bibr137-15330338231178403
  doi: 10.2147/CMAR.S216220
– volume: 10
  issue: 1
  year: 2022
  ident: bibr95-15330338231178403
  publication-title: Gastroenterol Rep
– ident: bibr66-15330338231178403
  doi: 10.1093/annonc/mdx030
– ident: bibr151-15330338231178403
  doi: 10.1016/j.immuni.2016.01.024
– ident: bibr56-15330338231178403
  doi: 10.1016/S1470-2045(14)71168-4
– ident: bibr13-15330338231178403
  doi: 10.1038/s41374-022-00804-9
– ident: bibr100-15330338231178403
  doi: 10.1186/s13046-022-02591-z
– ident: bibr37-15330338231178403
  doi: 10.1016/j.critrevonc.2021.103537
– ident: bibr178-15330338231178403
  doi: 10.18632/oncotarget.17466
– ident: bibr102-15330338231178403
  doi: 10.1016/j.esmoop.2022.100400
– ident: bibr118-15330338231178403
  doi: 10.3390/scipharm90020036
– ident: bibr149-15330338231178403
  doi: 10.1056/NEJMoa1917239
– ident: bibr120-15330338231178403
  doi: 10.2174/1568009619666191114110359
– ident: bibr134-15330338231178403
  doi: 10.1111/cas.12907
– volume: 4
  start-page: 421
  issue: 1
  year: 2014
  ident: bibr179-15330338231178403
  publication-title: Adv Pharm Bull
– ident: bibr16-15330338231178403
  doi: 10.1053/j.gastro.2022.05.032
– ident: bibr87-15330338231178403
  doi: 10.1016/j.stemcr.2022.12.013
– ident: bibr127-15330338231178403
  doi: 10.1007/s12325-018-0791-0
– ident: bibr167-15330338231178403
  doi: 10.1200/JCO.2010.30.1366
– ident: bibr40-15330338231178403
  doi: 10.1016/j.ejmg.2019.103753
– ident: bibr162-15330338231178403
  doi: 10.1056/NEJMoa1908075
– ident: bibr38-15330338231178403
  doi: 10.1200/EDBK_349557
– volume: 32
  issue: 5
  year: 2021
  ident: bibr150-15330338231178403
  publication-title: Ann Oncol
– ident: bibr3-15330338231178403
  doi: 10.3390/cancers12092679
– volume: 71
  start-page: 434
  issue: 6
  year: 2017
  ident: bibr55-15330338231178403
  publication-title: Med Arch (Sarajevo, Bosnia Herzegovina)
– ident: bibr57-15330338231178403
  doi: 10.21037/jgo.2019.05.01
– ident: bibr80-15330338231178403
  doi: 10.1038/bjc.2015.399
– ident: bibr141-15330338231178403
  doi: 10.1056/NEJMoa2017699
– ident: bibr157-15330338231178403
  doi: 10.1158/2159-8290.CD-16-0795
– ident: bibr7-15330338231178403
  doi: 10.1016/j.semcancer.2022.03.018
– volume: 3
  start-page: 35
  issue: 1
  year: 2022
  ident: bibr43-15330338231178403
  publication-title: Journal of Epigenetics
– ident: bibr53-15330338231178403
  doi: 10.1136/gut.2010.217182
– ident: bibr29-15330338231178403
  doi: 10.3390/ijms23169302
– ident: bibr123-15330338231178403
  doi: 10.1007/s00384-021-04064-9
– ident: bibr168-15330338231178403
  doi: 10.1200/JCO.2013.48.9591
– volume: 77
  issue: 1
  year: 2022
  ident: bibr93-15330338231178403
  publication-title: Tissue Cell
– volume: 19
  start-page: 774
  issue: 12
  year: 2021
  ident: bibr177-15330338231178403
  publication-title: Clin Adv Hematol Oncol
– ident: bibr39-15330338231178403
  doi: 10.1002/ijc.33599
– ident: bibr45-15330338231178403
  doi: 10.1038/s12276-022-00731-1
– ident: bibr26-15330338231178403
  doi: 10.1126/science.1096502
– ident: bibr47-15330338231178403
  doi: 10.1002/path.5868
– ident: bibr1-15330338231178403
  doi: 10.3390/cancers14071732
– ident: bibr160-15330338231178403
  doi: 10.3390/cancers12041022
– ident: bibr86-15330338231178403
  doi: 10.1016/j.tig.2022.02.010
– ident: bibr104-15330338231178403
  doi: 10.15252/msb.20145645
– ident: bibr119-15330338231178403
  doi: 10.3390/ijms23136911
– ident: bibr185-15330338231178403
  doi: 10.1002/jcb.27275
– ident: bibr188-15330338231178403
  doi: 10.1001/jamaoncol.2015.5511
– ident: bibr24-15330338231178403
  doi: 10.1053/j.gastro.2008.07.076
– ident: bibr88-15330338231178403
  doi: 10.1016/j.bbrc.2022.09.046
– ident: bibr99-15330338231178403
  doi: 10.3390/ijms23169455
– ident: bibr21-15330338231178403
  doi: 10.1056/EVIDra2100035
– volume: 9
  start-page: 1
  year: 2019
  ident: bibr133-15330338231178403
  publication-title: Front Oncol
  doi: 10.3389/fonc.2019.00001
– ident: bibr85-15330338231178403
  doi: 10.1038/s41418-022-00975-4
– ident: bibr108-15330338231178403
  doi: 10.3390/ijms20122919
– ident: bibr69-15330338231178403
  doi: 10.1186/s12885-022-09947-w
– ident: bibr161-15330338231178403
  doi: 10.1158/1078-0432.CCR-14-2779
– ident: bibr52-15330338231178403
  doi: 10.1146/annurev-pathmechdis-012418-012818
– ident: bibr5-15330338231178403
  doi: 10.1080/13543784.2022.2040016
– ident: bibr41-15330338231178403
  doi: 10.1073/pnas.96.15.8681
SSID ssj0026631
Score 2.5194275
SecondaryResourceType review_article
Snippet Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are ineffective in all cases. The genomic profile and biomarkers associated with...
SourceID doaj
swepub
pubmedcentral
proquest
pubmed
crossref
sage
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 15330338231178403
SubjectTerms Advances in the Diagnosis and Treatment of Gastrointestinal Cancers
Biomarkers
Biomarkers, Tumor - genetics
Cancer therapies
Chemotherapy
Colon cancer
Colonic Neoplasms - diagnosis
Colonic Neoplasms - genetics
Colonic Neoplasms - therapy
Colorectal cancer
Epigenetics
Genetic diversity
Health care
Humans
Immunotherapy
Patients
personalized treatment
Precision medicine
Precision Medicine - methods
targeted therapy
Transcriptomics
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3di9QwEA96gvgiftvzlAiiIFdMm6Rpn2RdXQ5BuYc72beSNIkuHu25Hy_3199Mmu5S7liftqSzaTqdTH7JZH4h5J3SuLgvRcobaVJhYcJqYJRMGfPMAkDmpQ5snz-Lk3PxfS7nccFtFbdVDj4xOGrbNbhG_gkDYkVesrL6fPkvxVOjMLoaj9C4S-4hdRlu6VLz3YQLRtPIlwoP56KIUU0kXMIyxkMQLFMwyeGjcSnQ99-GOW9unYzJ-SOe0TA2zR6RhxFU0klvBY_JHdc-Ifd_xLD5U3IF4BBqopM-4B-y2o5pyG3qF-yOqW4tnQV-EXq6y79c0c5TgIh0s3J4eTpA9ytn6VA_XbT0bNivjlJTcKgtneKjls_I-ezb2fQkjYcupE0h1DrNKl-6olJVrk3BuOROWoAtVjmbKdbIisN0Wjrhc--8ESbXEpRRFCCVe9V4_pwctF3rXhKqcpdZIbw1oHztwRN4422mw69RNiFsUHndxBfGgzEu6iySkN_4Sgn5uP3LZU_HsU_4C37HrSAyaYeCbvm7jh2z5hoQIdOlkB7AFOMGmgeopqkMk66SMiFHgxXUsXuv6p0xJuTt9jZ0TIy26NZ1G5TJYXoI_hBkXvRGs20JV7koAUsmpByZ06ip4zvt4k8g_84CKV2ZJeQDWt6uTXvU8L43zlHtXxe_JkERF4tNjbHUvPqPYLcEQYB_rLxdMBb9hStXF5jyXB3uV94r8iAHzNivaB2Rg_Vy414DxlubN6EjXwMmXEuZ
  priority: 102
  providerName: ProQuest
– databaseName: Sage Journals Online Open Access
  dbid: AFRWT
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfGJiFeEN8EBjISAgktzPFn8oRKoZqQQBPqYG9RHNtQsSWobR7YX8_ZcTpFqwZPjZyrc7nc2T_7PozQS1X5zX3BU1YLnXIDC1YNs2RKiCMGADLLq1Dt84s8OuGfTsXpDmqHXJgowdVbH1YFHIXB2lu3340-jE7GQw9SCAsurEzBEoW969bnZb_dPZyq4Vu8f7o7967t2gdE_kmH9LYbaI8qKcCS9yazr9_nmzUaTMCxxCrwy7iMjtCtDx1NZaHi_zaYejXaMubzj0qThulsdgfdjjgUT3rFuYt2bHMP3fwcPe330QXgSegJT_oYgZAId4BDOlS_x3eAq8bgWShJgo8vUzZXuHUYUCXuVtZfHg9o_8IaPPSPFw2eDyHunmoKY3CDp_5RywfoZPZxPj1K4zkNaS25WqdZ4XIrC1XQSkvCBLPCANIxyppMkVoUDFbgwnJHnXWaa1oJEIaUQEWdqh17iHabtrGPEVbUZoZzZzQIv3IweDjtTFaFX61Mgsgg8rKOL-zP0jgrs1i3_MpXStCbzV9-9xU8riN-77_jhtAX3w4N7fJHGW25ZBWASFLlXDjAX4RpYA-AUF1oImwhRIL2By0oB30uvUNX0pzkRYJebG6DLXsHTdXYtvM0FFaUMIQCzaNeaTacMEV5DvAzQflInUasju80i5-hXngW6tjlWYJee8275OkaMbzqlXPU-4fFt0kQxNmiK737lRb_IGyXQAiIkeTbCWPTL7iypfRZ0sWT_2byKbpFAXH2-2H7aHe97OwzQIhr_Txa9V89oV8H
  priority: 102
  providerName: SAGE Publications
Title Recent Advancements, Limitations, and Future Perspectives of the use of Personalized Medicine in Treatment of Colon Cancer
URI https://journals.sagepub.com/doi/full/10.1177/15330338231178403
https://www.ncbi.nlm.nih.gov/pubmed/37248615
https://www.proquest.com/docview/2890628089
https://www.proquest.com/docview/2820967879
https://pubmed.ncbi.nlm.nih.gov/PMC10240881
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-195329
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-106108
http://kipublications.ki.se/Default.aspx?queryparsed=id:152783934
https://doaj.org/article/3a6440a845f74303ba93241c9b05e955
Volume 22
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBdbB2MvZd2nuzZoMDYYNZMsybIf06yhDFZCSbe8GcmSWGhxSj5e-tfvJMvpTEv7sicb-6Iop1PudzrdTwh9ksov7gueslrolBsIWDV4yZQQRwwAZFaowPZ5lp9e8B8zMfvnqC-_J6ylB24V940p8NhEFVw4cHaEaQWIg9O61ETYUgT2UvB5XTAVQy3wozTmMD29kgc1hIWUF5UQ0rCeFwpk_fchzLsbJWMpfo9VNHii8Uu0GyEkHrZd30NPbPMKPf8Zk-Sv0Q1AQWgJD9v0fqhhO8KhkqldnjvCqjF4HNhE8OS22nKFFw4DIMSblfW3kw6o31iDu_bxvMHTbne6lxrB32eDR_6rlm_QxfhkOjpN4xELaZ1zuU5p6Qqbl7LMlM4JE8wKAyDFSGuoJLUoGQTPwnKXOes015kSoIw8B6nMydqxt2inWTT2PcIys9Rw7owmjCsH895pZ6gKVy1Ngkin8qqOP9gfg3FV0Ug5fmeUEvR1-5HrlnzjIeFjP45bQc-bHR6ANVXRmqrHrClBB50VVHEyryqfi82zghRlgj5uX8M09LkV1djFxsuAFYLjlyDzrjWabU-YzHgByDFBRc-cel3tv2nmfwLVNw0UdAVN0Bdvebd9ekANn1vj7LX-ff5rGBRxNd9UPnOalY8ILpYgCGCPFPcLxkeXcGer3Bc4l_v_YwQ-oBcZ4Mh2lesA7ayXG3sIuG-tB-ipnMkBejYcn_-ewvX45GxyPggT_y9T7VTh
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJ8FeEPcFBhiJi4QW4fiSywNCXbeqY1tVoQ7tLSSxDRVTMnoRYj-K38ix47SKNpWnPTVyThzHPj3nOz72Z4ReR5mZ3BfcZ4XIfS4hYM3BS_qEaCIBILM4s2yfw3Bwyj-fibMN9LfZC2OWVTY20RpqWRVmjvyDSYiFNCZx8unil29OjTLZ1eYIjVotjtSf3xCyzT4e7sP4vqG0fzDuDXx3qoBfhDya-0GiYxUmUUKzPCRMMCUk-GUZKRlEpBAJg3hRKK6pVjrnOc2ELFQYghTVUaEZ1HsLbXIGoUwHbe4dDEdfliEe-G_H0Aqfy3jo8qiG4smUEWbTbkEEYRVreUJ7YMB1KPfqYk1HB9BiNrXesH8P3XUwFndrvbuPNlT5AN0-cYn6h-gS4CjUhLv1EgO7j24X291U9RThLs5KifuW0QSPVjs-Z7jSGEApXsyUuRw1wcKlkripH09KPG5WyBupHpjwEvfMq6aP0OmNDMhj1CmrUm0jHFEVSM61zKHzMw22R-daBpn9zSPpIdJ0eVq4DzZHcZyngaM9vzJKHnq_fOSiJgBZJ7xnxnEpaLi7bUE1_Z46U5CyDDAoyWIuNMA3wnJoHuCoIsmJUIkQHtpptCB1BmWWrtTfQ6-Wt8EUmPxOVqpqYWQoBKRggUHmSa00y5awiPIY0KuH4pY6tZravlNOfli68cDS4MWBh94ZzVu1aU03vK2Vs1X7_uRr13bE-WSRmuwtTf4jWE1BEAAnia8XdEU_4UqlodlknTxd33kv0Z3B-OQ4PT4cHj1DWxQQaz2ftoM68-lCPQeEOc9fuL81Rt9u2pL8A9HxijI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZgK1VcEG8CBYyEQEJN6_gRJ8dlS1Re1Qptobcojm1YUSXVPi799YwdZ6uoq8Jpo2TWmUzGns8ezxeE3sjKLe4LHrNaqJhrmLAqiJIxIZZoAMgsqzzb50l6fMo_n4mzsODmamGCBZcHblsVaOQHa9e7L7Q9DDnGQ4dRCPMZrETCDIXdRjucQ2wcoZ1x8f3nbDPlgngaGFPh9oynIa-5tZFBZPIE_ttQ5_XNk6E8f8A06qNTcQ_dDbASjzs_uI9umeYB2v0WEucP0SXAQ2gJj7uUv69r28e-uqlbstvHVaNx4RlG8PSqAnOJW4sBJOL10rjDaQ_eL43Gfft43uBZv2PdSU1gSG3wxN1q8QidFh9nk-M4fHYhrlMuV3GS28ykucxppVLCBDNCA3DR0uhEklrkDCbUwnBLrbGKK1oJMEaaghS1srbsMRo1bWOeIiypSTTnViswfmVhLLDK6qTyv0rqCJHe5GUdHth9GuO8TAIN-bW3FKH3m79cdIQcNwl_cO9xI-i4tP2JdvGrDF2zZBVgQlJlXFiAU4QpUA9wTZ0rIkwuRIT2ei8oe_csXX42pRnJ8gi93lyGrunyLVVj2rWToTBBhBERZJ50TrPRhEnKM0CTEcoG7jRQdXilmf_29N-Jp6XLkgi9c553pdMNZnjbOeeg9aP5j7E3xPl8XbpsKs3_IdguQBAAIMm2C4ZTf-DIlKkres6f_beSr9Du9Kgov346-fIc3aGAJbuVrj00Wi3W5gVgv5V6GTr4X1UNTYA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Recent+Advancements%2C+Limitations%2C+and+Future+Perspectives+of+the+use+of+Personalized+Medicine+in+Treatment+of+Colon+Cancer&rft.jtitle=Technology+in+cancer+research+%26+treatment&rft.au=Dey%2C+Amit&rft.au=Mitra%2C+Abhijit&rft.au=Pathak%2C+Surajit&rft.au=Prasad%2C+Suhanya&rft.date=2023&rft.pub=SAGE+Publications&rft.issn=1533-0346&rft.eissn=1533-0338&rft.volume=22&rft_id=info:doi/10.1177%2F15330338231178403&rft_id=info%3Apmid%2F37248615&rft.externalDocID=PMC10240881
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1533-0346&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1533-0346&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1533-0346&client=summon